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Growth failure is frequently encountered in children with chronic inflammatory conditions like juvenile idio-
pathic arthritis, inflammatory bowel disease and cystic fibrosis. Delayed puberty and attenuated pubertal
growth spurt is often seen during adolescence. The underlying inflammatory state mediated by pro-inflam-
matory cytokines, prolonged use of glucocorticoid and suboptimal nutrition contribute to growth failure and
pubertal abnormalities. These factors can impair growth by their effects on the growth hormone-insulin like
growth factor axis and also directly at the level of the growth plate via alterations in chondrogenesis and local
growth factor signaling. Recent studies on the impact of cytokines and glucocorticoid on the growth plate
studies further advanced our understanding of growth failure in chronic disease and provided a biological
rationaleof growthpromotion. Targeting cytokines usingbiologic therapymay lead to improvementofgrowth
in someof these childrenbut approximately one third continue togrow slowly. There is increasingevidence that
the use of relatively high dose recombinant human growth hormone may lead to partial catch up growth in
chronic inflammatory conditions, although long term follow-up data is currently limited. In this review, we
comprehensively review the growth abnormalities in children with juvenile idiopathic arthritis, inflammatory
bowel disease and cystic fibrosis, systemic abnormalities of the growth hormone-insulin like growth factor axis
and growth plate perturbations. We also systematically reviewed all the current published studies of recom-
binant human growth hormone in these conditions and discuss the role of recombinant human insulin like
growth factor-1.
I. Introduction
IMPAIRED LINEAR GROWTH is commonly encoun-tered in childrenwith chronic inflammatory conditions
such as juvenile idiopathic arthritis (JIA) (1) inflammatory
bowel disease (IBD), especially thosewithCrohn’s disease
(CD) (2, 3) and cystic fibrosis (CF) (4, 5). This may be
associated with delayed onset of puberty and attenuated
pubertal growth spurt (6), especially in those with IBD as
these children tend to present in late childhood and ado-
lescence [Figure 1]. Poor growthmay lead to short stature
and a reduction in adult height is seen in a sub set of these
patients despite contemporary medical therapy (7–9)
which may have an impact on their quality of life (QOL)
(10).
Suboptimal nutrition, prolonged use of glucocorticoid
(GC) and chronic inflammation itself contribute to the
underlying pathophysiology of growth failure (11, 12).
This may be through effects on the systemic growth hor-
mone (GH) axis that regulates linear growth or through
direct effects at the level of the growth plate (13) [Figure
2]. Chronic inflammation may lead to a continuum of
abnormalities in the systemic GH/ insulin like growth fac-
tor-1 (IGF-1) axis including relative GH insufficiency,
GH/IGF-1 resistance due to impairment of IGF binding
proteins, down regulation of GH/IGF receptors and / or
impairment of local GH and IGF-1 signaling pathways
[Figure 3].
Determining the prevalence of growth failure from cur-
rent published studies in children with JIA, IBD and CF is
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very challenging due to the different definitions used.
Studies defining growth failure based on stature are not
helpful, as this may underestimate the prevalence of fal-
tering growth, given that a child with relatively normal
height may have been growing very poorly over a period
of time. Stature also needs to be interpreted in the context
of the child’s midparental height.
Evaluating growth rate (height velocity)maybe a better
method to determine the prevalence of growth failure but
in a group of children where a degree of delayed puberty
maybe relatively common, comparing height velocity
(HV) purely based on age and gender may be misleading.
Due to the unpredictability of the inflammatory process,
HV is also likely to vary depending on the disease status
Figure 1.
Age Of Presentation Of Chronic Disease In Childhood
CF: CF, DMD: duchenne muscular dystrophy (MD); JIA: juvenile idiopathic arthritis; CRI: chronic renal insufficiency; IBD: inflammatory bowel
disease; SLE: systemic lupus erythematosus (SLE); CTD: connective tissue diseases
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rather than time course from diagnosis compared to other
conditions where treatment protocols may be fixed (eg,
childhood cancers). HVneeds to be interpreted in the con-
text of pubertal staging or bone age as it varies according
to gender and pubertal status (14). In healthy girls, peak
HV is attained at the age of approximately 12 years, cor-
responding to early breast stage (stage 2) whereas in
healthy boys this is usually at the age of 13.5 years cor-
responding to later stages of puberty (genital stage 4,
10–12ml testes) (15, 16). There is no consensus regarding
themost appropriatemethod to interpretHV in these chil-
dren. In addition, normative data for HV are from small
groups of children evaluated in the 70s.
Consideration must be given to bone age assessment in
children with chronic disease. Interpretation of bone age
may be inaccurate if performed in the hand affected by
arthritis (17). The use of change in height (Ht) SDSmaybe
a better method of defining growth problems in longitu-
dinal growth studies in children with chronic disease as
recently suggested as a way to report response to growth
promoting therapy (18) but may also need to be inter-
preted in the context of puberty and/or skeletal matura-
tion for adolescents.
Targeting the inflammatory process aggressively using
immunomodulators (eg, azathioprine, methotrexate) and
anticytokine therapy (eg, infliximab, etanercept, adali-
mumab), minimizing the use of systemic GC to achieve
adequate control of inflammation and optimizing nutri-
tion may be associated with improvement in markers of
the GH-IGF axis and are paramount for ensuring normal
growth and pubertal development (19, 20). However, al-
most one third of children with JIA and CD treated with
contemporary regimens continue to grow slowly (18) and
improvement in disease activity does not seem to normal-
ize linear growth in these children (21, 22). In adolescents
with CF, faltering growth often precedes the diagnosis of
CF relateddiabetes (23).While treatmentwith insulinmay
improve lung function and bodymass index (BMI) in chil-
dren with CF related diabetes (24, 25), the impact of in-
sulin on improving growth and pubertal development is
still unclear (23). In an individual with CF and faltering
growth, assessment of glucose homeostasis should be per-
Figure 2.
Mechanism Of Growth Failure In Chronic Inflammatory Disease
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formed to excludeCFdiabetes.Optimizationofmetabolic
control with insulin should be performed in those already
with established CF related diabetes and poor growth.
Pubertal induction with sex steroid may be considered
in those individualswho are growing slowly in association
with delayed puberty despite optimization of disease sta-
tus and nutrition, although the timing, route of adminis-
tration, dose of sex steroid and duration of treatment is
unclear. Abnormal bone development is also seen in these
adolescents (26–28) and in these individuals with chronic
disease, decisions regarding pubertal induction will also
need to include careful assessment of bone mass and the
potential benefit of sex steroid on bone acquisition. It is
beyond the scope of this current review to address issues
of pubertal induction in chronic diseasewhichwe feel is an
area of research often neglected.
The availability of recombinant human growth hor-
mone (hGH) (rhGH) in the past 30 years has led to its use
in nongrowth hormone deficient conditions (29) such as
Turner Syndrome (30–32), small for gestational age
(SGA) (33, 34), idiopathic short stature (35), short stature
homeobox (SHOX) deficiency (36), Prader Willi Syn-
drome (37) and chronic renal insufficiency (38). In
younger prepubertal children with chronic disease and in
those with pubertal delay who continue to grow slowly
despite pubertal induction, rhGH may be a therapeutic
option. Emerging therapeutic clinical trials of rhGH in
pediatric JIA, IBD and CF suggest that short term linear
growth may improve with rhGH therapy. These studies
demonstrate that rhGH, especially at a higher dose, may
be able to overcome the relative GH resistant state seen in
chronic disease (39).
The review aims to provide the most up to date sum-
mary of growth failure, systemic abnormalities in theGH/
IGF-1 axis and local growth plate disturbances observed
in children with JIA, IBD and CF. In addition, we will
summarize and critically evaluate the published literature
on the role of rhGH and rhIGF-1 as growth promoting
therapies in these children.
This review is timely given thatmanagement of chronic
disease has changed significantly over the last 15 years.
Modern therapies have opened up the therapeutic options
of management of these childhood chronic disease but a
subset are still non responders to these treatment and in
Figure 3.
Multiple Level Of Defect Of the GH/IGF-1 Axis In Children With Chronic Disease
GH: GH; IGF-1: insulin like growth factor-1; IGFBP: insulin growth factor binding protein
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some instances the occurrence of significant adverse ef-
fects preclude the use of these modern therapies. It is for
these reasons that poor growth and abnormalities of pu-
bertal developmentmay still be encountered and theman-
agement of these children and adolescents can be partic-
ularly complex. The full PubMed database was searched
with no time restriction in July 2015 using the following
keywords: inflammatory bowel disease, crohn’s disease,
crohn disease, ulcerative colitis, CF, juvenile idiopathic
arthritis, juvenile arthritis, juvenile rheumatoid arthritis
(RA) in combination with GH, insulin like growth fac-
tor-1 and IGF-1.Non-English articles were excluded. Rel-
evant articles were obtained and information synthesized
into this literature review by the authors.
2. Background physiology of normal linear growth
In this section, we will review the normal regulation of
linear growth via systemic and local factors. The reader is
however referred to other recent thorough and excellent
reviews on this area (40–42). It is generally accepted that
theGH/IGF-1 axis is amain regulator of linear growth via
its endocrine effects at a systemic level and also via local
autocrine/paracrine mechanisms. Understanding of the
systemic and local regulation of normal linear growth has
advanced significantly over recent years. Information on
how the systemicGH/IGF-1 axis interactswith local para-
crine factors in the regulation of normal linear growth is
still unknown. Chronic disease via chronic inflammation,
glucocorticoid and poor nutrition can impact growth at
multiple levels via their effects on the GH/IGF-1 axis sys-
temically and at the level of target organ.
2.1 Systemic regulation of linear growth
The endocrine regulation of normal linear growth in-
volves pituitary derived GH and the IGF system. It was
initially thought that GH itself did not exert its effects
directly on target organs but did so via IGF-1, produced in
the liver. It is now known that both GH and IGF-1 exert
separate and independent effects ongrowth.GHcanact to
induce the expression and action of local IGF-1 at the level
of the growth plate to lead to increase bone growth (43).
Local injection of GH directly into cartilage growth
plates of the hind limbs of hypophysectomised rats pro-
duced significant increase in lengths of the injected limb
comparedwith the non injected contra lateral limb, point-
ing to the direct effect of GHon regulating growth (44). In
addition, if all the growth promoting actions of GH are
mediated by IGF-1, then the GH receptor and IGF-1 null
mice should be similar to the double GH receptor and
IGF-1 receptor mutant mice (45). Lupu et al showed that
post natal mice with combined GH receptor gene and
IGF-1 gene deletion had the smallest size, whereas mice
with GH receptor gene deletion only were larger in size
than those with IGF-I gene deletion (45). Several other
groups also found that body size and tibial growth rate of
mice with GH gene deletion were lower than those with
IGF-I gene deletion (46–48). Numerous studies have pro-
duced conflicting results and are unable to pinpoint to the
precise mechanism of the action of GH and IGF-I on the
epiphyseal growth plate (49, 50).
The relative contribution of hepatic generated IGF-1 to
epiphyseal bone growth is currently unclear (51). In the
liver IGF-I deficient (LID) mice, deletion of the liver gene
of IGF-I reduced circulating IGF-I to 25%of thewild type
mice. Bone length and body size of the LID mice were not
different from thewild typemice. IGF-ImRNAexpression
in a variety of tissues including heart, muscle, fat, spleen
and kidney were similar between the LID mice and the
wild type mice, suggesting that there is no compensation
from IGF-I derived from other tissues accounting for the
preservation of linear growth in the LIDmice (52). A com-
bined knock out of LID, acid labile subunit knock-out
(ALSKO), IGF binding protein 3 knock-out (BP3KO) had
significantly reduced systemic levels of IGF-1 but only a
modest degree of growth retardation, pointing to the pos-
sibility of the importance of local factors regulating bone
growth (53).
Mice with targeted deletion of IGF-I in chondrocytes
had normal systemic levels of IGF-I but 40% reduction in
local IGF-I. Body length was however reduced by 27%
(54). On the other hand, elevated systemic levels of IGF-1
were able to rescue the growth impairment in IGF-1 null
mice pointing to the role of systemic IGF-1 on autocrine/
paracrine effects (55). The IGF-1 null mice also have com-
pensatory increase in local IGF-2 locally which may ex-
plain the modest growth impairment in that model. GH
promote growth plate chondrogenesis independent of lo-
cal IGF-1 and IGF-2 levels (56) and addition of rhIGF-1 to
rhGH treatment in healthy female mice did not lead to
improvement in bone growth (57). A study in a knock in
mouse model of mutated IGF-1 with markedly low total
IGF-1 and formation with IGFBPs but high levels of un-
bound IGF-1 showed significantly increased body size
pointing to the role of free bioavailable IGF-1 on regula-
tion of growth (58)
It has been suggested that an element of redundancy
may exist between local and endocrine growth factors like
IGF-1,where the absence of one source (systemic vs. local)
may be compensated by the other. The regulation of GH
and IGF-1 systemically and at local level may differ in
health and in chronic disease (41).
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2.2 Growth plate
The process of bone growth relies upon chondrocytes
produced at the epiphyseal growth plate, which are pro-
gressively synthesized and replaced by bone with accom-
panying longitudinal (endochondral) bone growth.
Growth plate (epiphyseal plate) is a layer of hyaline car-
tilage in growing bone located in the metaphysis between
the epiphysis anddiaphysis. It is left over cartilage fromthe
endochondral ossification. The epiphyseal plate consists
of four zones (59)
The zone of resting cartilage is near the epiphyses and
consists of a small, scattered chondrocytes. These cells do
not function in bone growth therefore; these are termed as
“resting”. Resting zone chondrocytes replicate at a slow
rate (60) and act as stem cells that replenish the pool of
proliferative chondrocytes (61).
The zone of proliferating cartilage consists of slightly
larger chondrocytes arranged like stack of coins. Chon-
drocytes divide to replace those that die at the diaphyseal
surface of the epiphyseal plate. Proliferative zone chon-
drocytes replicate at a high rate and the cells line up along
the long axis of the bone (60, 62)
The zone of hypertrophic cartilage consists of even
larger chondrocytes that are also arranged in columns.
The lengthwise expansion of the epiphyseal plate is the
result of cell division in the zone of proliferating cartilage
and maturation of the cells in the zone of hypertrophic
cartilage. During the hypertrophic phase, chondrocytes
increase their height about 6–10 fold. Hypertrophic dif-
ferentiation makes a significant contribution to longitu-
dinal growth (63). These chondrocytes calcify the sur-
rounding extracellular matrix and produce factors that
attract the invadingbone cells andbloodvessels (64). Prior
to blood vessels invading the chondrocytes lacuna, they
undergo apoptosis (65)
2.2.1 Local growth plate regulation
GH acts locally to recruit resting chondrocytes into the
proliferative state as well as stimulate local production of
IGF-which in turn stimulates proliferationof proliferative
chondrocytes. Infusion of IGF-1 to hypophysectomized
rats stimulate chondrocytes at all the stages of differenti-
ation, including the hypertrophic zone, clearly pointing to
a role of IGF-1 at the local level (66, 67).
At a local level, GH action may be regulated by sup-
pressor of cytokine signaling 2 SOCS2) (68). The SOCS2
knockout mice exhibit an overgrowth phenotype associ-
ated with increased GH/IGF-1 signaling leading to wider
proliferative and hypertrophic zones of the growth plate
(69). Studies using chondrocytes andmetatarsals from the
SOCS2 knockout mice showed increased GH signaling
locally and maybe independent of local IGF-1 (70).
The local regulation of growth also involves several
other paracrine signaling like fibroblast growth factors,
Indian hedgehog, parathyroid hormone-related protein,
bone morphogenetic proteins and vascular endothelial
growth factor (VEGF) (40). How these systems interact
with GH/IGF-1 regulation in health and disease is cur-
rently still unknown.
3. Inflammation and growth plate abnormalities
3.1 Effects of inflammatory cytokines on the growth
plate
Various cell and organ culture approaches have borne
evidence demonstrating the adverse effects of proinflam-
matory cytokines on growth plate chondrogenesis (71)
[Figure 4]. IL-1- and TNF decrease both the width of
the proliferating zone and the rate of endochondral bone
growth; a possible consequence of altered chondrocyte
proliferation, differentiation and apoptosis rates (71–74).
Furthermore, IL-1 and TNF reduce chondrocyte ex-
pression of cartilage matrix proteins including aggrecan
and collagen types-II and -X (71, 75, 76). The addition of
IL-6 alone appears to have little effect on growth plate
chondrocytes although it may be able to inhibit the early
differentiation steps of chondrocyte precursors (71, 73,
77–79). It is possible that IL-6 needs to be added in com-
bination with soluble IL-6R to have an effect on chondro-
cyte proliferation, differentiation and bone growth (73,
80, 81). Importantly both IL-1 and TNF- are also pro-
duced locally by growth plate chondrocytes to regulate
physiological bone growth and that the inhibition of en-
dogenous levels leads to improved longitudinal bone
growth (82, 83). The growth and long bone length of the
IL-1 receptor type 1 knock-out mouse were however nor-
mal despite a narrower growth plates due to a smaller
hypertrophic zone (84).
The direct analysis of proinflammatory cytokines on
linear bone growth has been aided by the study of cultured
fetal metatarsal bones. IL1-, IL-6 and TNF- inhibit lin-
ear growth and in combination they have an additive
growth inhibitory effect (71, 73, 81). Furthermore,TNF-
and IL1- also act in synergy to induce IL-6 production in
fetal metatarsals (81). There is also restricted potential for
recovery of growth plate chondrogenesis and longitudinal
bone growth following prolonged exposure to proinflam-
matory cytokines (71) [Figure 5]. This mirrors the clinical
impression of greater degree of growth impairment in
those children with longer periods of symptoms prior to
diagnosis (85).Additionof antibodies toTNF-and IL1-
lead to partial rescue of bone growth in the metatarsal
model (73) [Figure 6a].
In addition to analyzing the effects of recombinant cy-
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tokines on metatarsal growth, approaches using biologi-
cal fluids from children with JIA have also been informa-
tive. These preliminary studies disclosed that serum from
affected children disturbed chondrogenesis and linear
bone growth. The results with synovial fluid were less
consistent, emphasizing the interindividual variation of
the observed effects (86). As opposed to the partial rescue
of bone growth in metatarsals exposed to cytokines
(TNF- and IL1-), addition of antibodies to TNF-,
IL1- and IL-6 failed to show any improvement in meta-
tarsal growth when exposed to biological fluid from a
child with systemic JIA where a whole range of inflam-
matory cytokines may be detected other than TNF-,
IL1- and IL-6 (86) [Figure 6b].
Inflammatory cytokines may disrupt growth plate
function by inhibiting IGF-1 intracellular signaling (87,
88). Evidence for this is however limited as neitherTNF-,
IL-6 nor IL-1 appear to affect IGF-1 receptor expression
(71, 74, 89–91). Alternatively, proinflammatory cyto-
kines may disrupt signaling downstream of the IGF-1R.
TNF-, IL-6 and IL-1 can attenuate IGF-1-induced ac-
tivation of both the MAPK/ERK 1/2 and the PI-3K path-
ways in chondrocytes (74, 92). In myoblasts, IL-1 can
inhibit the ability of IGF-1 to phosphorylate tyrosine res-
idues on both of its downstream docking proteins, IRS-1
and IRS- 2 but it is as yet unknown if this also occurs in
chondrocytes (87). Proinflammatory cytokines may also
disrupt chondrocyteGH signaling. IL-6 and oncostatinM
can activate JAK/STAT signaling leading to down-regu-
lation of type II collagen, aggrecan core, and link protein
transcription in articular chondrocyte (80, 93). Likewise,
IL-1 can antagonize GH signaling through STAT5 in
hepatocytes while activating STAT3 in mouse kidney tu-
mor cells (94, 95). While the mechanisms by which JAK/
STAT signaling is blunted in inflammatory conditions are
unclear, there is an emerging body of evidence implicating
a role for the SOCS family of proteins which can inhibit
JAK2 and STAT activation in a negative feedback loop,
and whose expression is stimulated proinflammatory cy-
tokines (96–101).
3.2 Effects of glucocorticoid on the growth plate
The growth-suppressing effects ofGC appearmultifac-
torial with some GC actions modifying skeletal responses
Figure 4.
Effects Of TNF And IL1 On ATDC5 Cell Line Chondrogenesis
MacRae VE et al J Endocrinol 2006; 189: 319–2871
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to the GH/IGF-I axis whereas other evidence indicates a
direct effect of GH on growth plate chondrocytes. Com-
mon to both mechanisms is the interaction of GC with its
cytosolic receptor (GR)which results in themodulation of
gene transcription. This is accomplished via several dif-
ferent mechanisms. First, GCs bind to a cytosolic GC re-
ceptor attached to a heat-shock protein (HSP). The HSP
dissociates, and the GR dimerizes and translocate to the
nucleus and binds to promoters on the target gene known
asGCresponse elements (GRE), resulting in the activation
or repression of a specific set of transcription factors (102,
103). It has also been shown that the GR is capable of
binding directly to specific transcription factors such as
nuclear factor-B (NFB) and activator protein-1 (AP-1)
which are involved in the up-regulation of inflammatory
genes.Thismechanism is ligand-independent anddoesnot
require receptor dimerization, therefore rendering it ge-
netically separable from transcriptional activation (104).
GCs block the activation of the GH-receptor (GHR)
and the IGF-1 receptor (IGF-IR) in chondrocytes, inhibit
pulsatile GH release and reduce IGF-1R andGHRexpres-
sion by chondrocytes. GCs also impair IGF-1 signaling,
predominantly via the PI3K pathway at the growth plate
(92, 105–110). Studies of linear bone growth have shown
that dexamethasone (Dex) and IGF-1 have opposite ef-
fects, with Dex decreasing and IGF-1 increasing cell pro-
liferation. Furthermore, IGF-1 is able to ameliorate Dex-
induced growth impairment suggesting that IGF-1 may
protect the growth plate against the adverse effects of GC
(111).
Evidence for a direct effect of GC on the growth plate
comes from a study in which pharmacological levels of
local Dex infusion significantly decreased tibial growth
compared with the contralateral limb (112). The GR has
since been localized to proliferating and hypertrophic
chondrocytes in the rat (113) aswell as hypertrophic chon-
drocytes in the human growth plate (114). GC inhibit
chondrocyte proliferation and differentiation while stim-
ulating chondrocyte apoptosis and autophagy (105, 110,
111, 115–117). The inhibitory effects of GCs on chon-
drocyte proliferation are consistent with GCs disrupting
cell cycle progression and promoting cell cycle exit (118,
Figure 5.
Effects of TNF and IL1 in the metatarsal model depending on days of exposure to cytokine
MacRae Ve et al J Endocrinol 2006; 189: 319–2871
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119). While chondrocyte p21 expression is increased by
Dex this increase does not contribute to GC-induced
growth retardation (120, 121). The role of other cyclin
dependent kinase inhibitors such as p27 in mediating GC
inhibition of chondrocyte proliferation has also been
questioned (122).
GCs may stimulate apoptosis by altering the relative
amounts of proapoptotic members of the Bcl-2 family
such as Bax and Bid and thereby promote mitochondrial
apoptosis (123, 124). The Bax deficient mice display re-
sistance to GC induced growth failure, confirming that
increased apoptosis as a crucial factor in GC induced
growth impairment. (123) The global effects of pharma-
cological GC doses on chondrocyte gene expression have
been investigated using microarray technologies. Both
down-regulated genes such as secreted frizzled-related
protein and IGF-I, andupregulatedgenes including serum/
GC-regulated kinase, connective-tissue growth factor and
lipocalin 2 have been identified (125, 126).
Novel GCs that have the anti-inflammatory properties
of conventional steroids without one or more of the side-
effects have been described (127, 128). One of these com-
pounds AL-438 acts through the GR
and while retaining full anti-inflam-
matory efficacy it has a GC sparing
effect on chondrocyte proliferation
and longitudinal bone growth (115,
129). This, and similar compounds,
could prove important in the search
for new anti-inflammatory treat-
ments for children. GC excess and
GH deficiency impair longitudinal
bone growth. After remission,
growth often accelerates beyond the
normal growth rate for that particu-
lar age, a phenomenon called
catch-up growth (130, 131). This
has also been observed in many
growth-retarding conditions such as
Cushing’s syndrome (132), hypothy-
roidism (133), celiac disease (134)
and anorexia nervosa/malnutrition
(132). However catch-up growth in
children with chronic inflammation
may not be complete even after dis-
continuation of GC treatment if the
inflammatory insult is ongoing,
which is often the case.
Studies in rabbits in which Dex
was infused directly in the tibial
growth plate resulted in slow bone
growth of the treated bone but not of
the contralateral vehicle-treated
bone (135). After cessation of Dex
infusion, tibial bone growth ratewas
increased compared with the con-
tralateral leg, thereby demonstrating
catch-up growth (136). Based on
these findings, Gafni and Baron
(137) proposed that the underlying
mechanism for catch-up growth was
intrinsic to the growth plate. Specif-
ically, the decrease in chondrocyte
Figure 6.
a: Effects of addition of antibodies to metatarsals exposed to TNF and IL1
Martensson K et al J Bone MinerRes 2004; 19:1805–1273
b: Effects of addition of antibodies to metatarsals exposed to synovial fluid of a child with
systemic JIA during acute relapse
MacRae VE et al Clin Endocrinol 2007; 67:442–886
PBS: phosphate buffered solution; SF-A: synovial fluid from child A; Ab: antibody
doi: 10.1210/er.2015-1026 press.endocrine.org/journal/edrv 9
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 08 January 2016. at 04:28 For personal use only. No other uses without permission. . All rights reserved.
proliferation noted during GC treatment conserves the
proliferative capacity of chondrocytes and delays chon-
drocyte senescence. Therefore, after discontinuation of
GC treatment, the growth plate chondrocytes are less se-
nescent ie, have greater proliferating potential and thereby
explaining the increased growth rate. In vitro studies have
also shown that Dex-treated cells retain the capacity to
re-enter chondrogenesis following the withdrawal of GC
(119). This implies that, although Dex arrests growth and
differentiation of chondrocytes, the capacity for cells to
undergo chondrogenesis is maintained in the presence of
GC despite the fact that progenitor cells are quiescent.
3.3 Effects of malnutrition on the growth plate
There is no doubt that undernutrition impairs skeletal
growth and contributes to the growth failure in children
with chronic disease. In a rat model of colitis, inflamma-
tion itself, independent of poor nutrition, explains 40%of
the growth impairment (138). Aggressive nutritional ther-
apies are often considered in children with IBD and CF,
including the use of supplemental feeds and gastrostomy
feeding. In the last few decades, in CD, the use of exclusive
enteral nutritional (EEN) during acute relapse is generally
used in place of oral GC as first line, except in those with
severe disease, in most countries (139).
Rat studies show that undernutrition lead to reduction
in GH production (140) but also reduction in hepatic GH
sensitivity due to decreased GH receptor mRNA in the
liver and resultant low systemic IGF-1 (141, 142). In hu-
mans, malnutrition is associated with hepatic GH resis-
tance but associated with elevated systemic GH levels
(143, 144). Short periods of fasting (2–3 days) in animal
studies report reduction in linear growth by 30% com-
pared with control animals, associated with reduction in
all zones of the growth plate and decrease in chondrocyte
number. In addition,GH receptor and IGF-1 expression is
reduced in growth plates of mice with food restriction
(145).
GH resistance during fasting maybe a metabolic adap-
tation and fibroblast growth factor 21 (FGF21) has been
identified as a key regulating factor inducing gluconeo-
genesis, fatty acid oxidation and ketogenesis. Short peri-
ods of fasting can lead to elevation of FGF21 (146, 147).
The link between FGF21 and growth is demonstrated by
the fact that transgenic mice over expressing FGF21 have
reducedbonegrowthandhepaticGHresistance (148).On
the other hand, FGF21 knockout mice subjected to 4
weeks of food restriction did not exhibit reduction in lin-
ear growth and did not show GH resistance (145). In-
creased FGF21 during periods of undernutrition affect
GHsensitivitybydirectly inhibitingGHbinding ingrowth
plate chondrocytes with no impact on the number of GH
receptors locally. This may be an indirect effect via the
effects of two transmembrane proteins, LEPROT and
LEPROTL1, which are increased during fasting, leading
to reduction in GHbinding and action at the growth plate
(149).Recently it has been shown that fasting is associated
with significant increase in microRNA-140 specifically at
the level of chondrocytes, although its precise mechanism
on malnutrition growth failure is still unclear (150).
4. Animal models of chronic disease and growth
disorders
Animalmodels of arthritis and colitis confirm thedirect
effects of chronic inflammation on growth, the GH/IGF
axis systemically and at a local level. In addition, they have
also provided evidence of the direct role of inflammation
on delayed puberty and poor pubertal growth.
The IL-6 transgenic mice have an adult size that is
50%–70% smaller compared to nontransgenic litter-
mates, even after controlling for food intake (151). This
was associated with normal systemic GH but low IGF-1
and low IGFBP-3. ALS levels on the other hand remained
normal (151, 152). The low IGF-1 was seen to be due to
increased renal clearance while the low IGFBP-3 was due
to increased proteolysis (152). Blocking IL-6 reversed the
growth phenotype and normalized IGF-1 levels, pointing
to the role of IL-6 on growth failure in chronic inflamma-
tion (153).
In a study of rats with Mycobacterium butyricum in-
duced arthritis,weight gainwas three fold lower than con-
trols. This was associated with low IGF-1 but increased
IGFBP-3 due to decrease in proteolysis (154–156). Pitu-
itary GH and liver IGF-1 gene expression were reduced
(157). In a studyusing amousemodel of systemic arthritis,
C-natriuretic peptide overexpression in chondrocytes pre-
vented endochondral growth retardation and reduced ar-
ticular cartilage damage (158). This is thought to be me-
diated via an increase in chondrocyte proliferation,
differentiation, hypertrophy,matrix production and local
resistance to the effects of proinflammatory cytokines
(158).
Following trinitrobenzenesulphonic acid (TNBS) in-
duced colitis, rats demonstrate growth retardation inde-
pendent of undernutrition, leading to only 30% of the
growth rate of healthy rats (159, 160), associated with
normal systemic GH levels but low IGF-1 (159). The IL-6
colitis rat also has 30% of the growth rate of controls,
associated with low IGF1 levels (161).
Studies in TNBS colitis rats and dextran sodium sulfate
(DSS) colitis demonstrated that inflammation causes de-
layed puberty inconsistent with changes in food intake,
body weight, leptin and corticosterone levels (162–164).
Plasma levels of 17-estradiol in females and testosterone
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inmale rats with colitis were significantly lower, although
basal gonadotropin levels were similar (162). In females
DSS mice with colitis, estradiol and gonadotropin levels
were not lower (164). InmalesDSSmicewith colitis, there
was nodifference in testosterone levels but stimulatedLH,
basal and stimulated FSH levels were lower in those male
mice (163). In our opinion, these animal data suggest that
cytokines may affect the secretion or sensitivity of gonad-
otropins, or act at the level of the gonadotropin releasing
hormone which may differ depending on gender. Admin-
istration of inflammatory cytokines (165, 166) via intra-
cerebroventricular injection and peripheral injection of
lipopolysaccharide (167)havebeen shown todecrease lev-
els of LHandFSH.AlthoughTNF- and IL1- can inhibit
steroidogenesis in leydig cells (168), the animal models of
colitis do not support an effect of cytokines on the gonads
causing primary gonadal failure as the etiology of delayed
puberty.
CF mice with a null mutation in the CFTR were signif-
icantly lighter and shorter compared with wild type mice
associated with significantly lower systemic IGF-1 levels.
Marginal reduction in GH levels were seen only in the
female mice (169). CF mice have mild pancreatic pathol-
ogywith little or no exocrinepancreatic dysfunction.They
however exhibit growth failure suggesting that pancreatic
exocrine status may not play a significant role in poor
growth in this animalmodel (170).A study in pigswithCF
demonstrated growth deficits at birth with associated
lower IGF-1 levels which is due to the lack of CFTR im-
pairing GH secretion (171).
Adjuvant induced arthritis in rats treated with rhGH
showed increased bodyweight (156, 172) associated with
increase levels of systemic IGF-1 and IGFBP-3 (156, 172),
with reduction in IGFBP-1 and IGFBP-2 (156). Also,
transgenic mice overexpressing GH with induced colitis
had similar weight trajectory as controls. Compared with
wild type mice with induced colitis, transgenic mice with
induced colitis had higher systemic IGF-1 levels (173). In
contrast, rhGH treatment in interleukin 10-null micewith
colitis improved weight gain but did not raise systemic
IGF-1 levels (174). While systemic IGF-1 levels were
higher in rhGH treated rats with colitis, they were still
lower than levels in control rats (175). In response to
rhGH therapy, animal models of colitis have reduced he-
patic activated tyrosine phosphorylated STAT5 (176,
177).Currently, there areno studies evaluating thegrowth
plate phenotype in animal models of chronic inflamma-
tion treated with rhGH. rhGH in rodent models may also
activate the prolactin receptor. To the best of our knowl-
edge, there are no animal studies of rhGH in chronic dis-
ease specifically targeting the GH receptor.
5. Juvenile idiopathic arthritis (JIA)
5.1 Disease and management
Juvenile idiopathic arthritis comprises a heterogeneous
group of disease subtypes involving inflammatory arthri-
tis’s beginning before the age of 16 years with symptoms
presenting for greater than 6 weeks (178). The pathogen-
esis is currently unknown although it is thought to be due
to a combination of environmental triggers and specific
immunogenic factors (179, 180). There are currently
seven subtypes of JIA according to the International
League of Associations for Rheumatology (ILAR) classi-
fication (178, 181, 182). In currently published literature
regardinggrowthandpubertal development, distinction is
generally only made between those patients with oligoar-
ticular, polyarticular and systemic JIA.
Management of JIA differs depending on the subtype.
There is currently no cure for JIA and treatment is focused
on achieving optimal function of joints, preserving or en-
suring normal mobility for day to day activity, ensuring
normal growth development andminimizing negative im-
pact on the child and family (183). Pain relief is achieved
with the use of nonsteroidal anti-inflammatory drugs
(NSAID).
In thosewithmore severe joint involvement that do not
respond to NSAID, intra-articular GC injection is used as
second line treatment. Response is usually seen within
daysof injectionanda response rate of 60%–70%ismain-
tained for several months (184–186). Early use of intra-
articularGC injections,may result in fewer local long term
consequences like contractures, muscle atrophy and leg
length discrepancy (187, 188). Reports of children treated
with intra-articular GC and development of Cushingoid
features exist in the published literature (189–191). The
effect of intra-articular GC injections on linear growth in
JIA is unclear.One studyof 21patients showedno adverse
effects on linear growth (192). In a report of 2 patients
with JIA (193), leg growth of the contralateral leg was
reduced using knemometry after intra-articular GC injec-
tion. This could reflect local overgrowth of the affected
inflamed limb which can occur in these children (194).
For those with severe arthritis, oral GCmay be needed.
In some instances, intravenous (IV) GC (methylpred-
nisolone) for a short periodmayalsobe required especially
awaiting the therapeutic effects of background immuno-
modulator(eg, methotrexate) (195). Other aspects of dis-
easemanagement in subtypes of JIAwill be summarized in
the next subsections.
5.1.1 Oligoarticular JIA
This is the commonest subtype of JIA accounting for
almost 50% of all children with JIA (196). These children
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have 4 joints or less affected. The arthritis is generally
asymmetrical and predominantly involves the large joints
of the lower extremities excluding the hips. Themost com-
monly affected joints in decreasing order are the knees,
ankles, elbows and the wrists (196, 197). A subgroup of
patients with oligoarticular JIA have extension of joint
involvement such that there is4 inflamed joints after the
first sixmonths of disease, termed extended oligoarticular
JIA. Approximately 50% of those who present with  4
inflamed joints at diagnosis show subsequent extension of
involved joints (198, 199). It is unclear if this is a separate
entity or if these patients in fact have polyarticular JIA.
5.1.2 Polyarticular JIA
This group of children with JIA have 5 or more joints
inflamed. All childrenwith polyarticular JIA generally are
likely to require a disease modifying antirheumatic drug
(DMARD) such asmethotrexate, sulfasalazine or lefluno-
mide; anti-TNF therapy eg, etanercept - or both classes of
drugs. It is not uncommon, especially in those with severe
disease, for a short bridging course of oral GC to be used.
Current data suggests thatmethotrexate is theDMARDof
choice in polyarticular JIA with approximately 86% re-
sponders at 2 years (200). Sixty three percent of children
with polyarticular JIA will respond to treatment with
methotrexate (201).
In those with recalcitrant disease, anti- (tumor necrosis
factor (TNF)) TNF therapy offers the possibility of im-
proving inflammation in these children. Etanercept (En-
brel) is the anti-TNF of choice in JIA. Etanercept is a sol-
uble, dimeric fusion protein consisting of the human p75
TNF receptor fused to the Fc region of the human IgG1.
Approximately 74% of children with methotrexate resis-
tant JIA will respond to treatment with etanercept (202,
203). Adalimumab (Humira), a humanized monoclonal
antibody against TNF-, has also been shown to be effec-
tive inmethotrexate resistant polyarticular JIA (204). Sev-
eral studies have demonstrated the efficacy of etanercept
in improving linear growth in children with JIA, mostly
children with polyarticular JIA (22, 205, 206). Improve-
ment in growth is greatest in those with lower Ht SDS at
baseline and those not treated with GC. Growth response
is modest, with a recent study from a large group of 191
children demonstrating that change in Ht SDS was only
0.29 SD after two years of therapy (22).
5.1.3 Systemic JIA
The initial description of children with systemic JIA
involves the observation of the classical triad of remittent
fever, typical macular, salmon colored rash and arthritis.
The arthritis could be oligoarticular initially but often
progress to polyarthritis with resulting significant defor-
mity leading to disability. The systemic signs of fever and
rash can precede arthritis up to several months. Growth
failure is frequently seen in children with systemic JIA,
especially during acute flare (207). Predictors of poor
prognosis in systemic JIA include age of onset  6 years,
disease duration 5 years or persistent systemic features
at 6 months of disease including fever, need for GC and
thrombocytosis (208). While anti-TNF therapy is often
used as first line biologic agent in systemic JIA, it is gen-
erally less effective compared to polyarticular JIA. 54%of
patients with systemic JIA show poor response to etaner-
cept (209)
Evidence suggests that systemic JIA is in fact more
driven by IL1- and IL-6 (210, 211). Anakinra (Kineret)
is a recombinant human (rh) IL-1 receptor antagonist
shown to be effective in several preliminary open label and
retrospective studies of children with GC dependent sys-
temic JIA (211–213). Two recent randomized trials of
Anakinra in children with systemic JIA have documented
its efficacy in reduction of inflammation (214, 215). Only
about 45% of these children are IL-1 blocker responders
and responders are those with lower number of active
inflamed joints, higher absolute neutrophil count (212),
suggesting that IL-1 may not be the only driving cytokine
in some children with systemic JIA.
In systemic JIA, elevated levels of IL-6 have also been
seen and appear to correlate with arthritis, fever and
thrombocytosis (216). Tocilizumab (Actemra) is a hu-
manized monoclonal antibody against the IL-6 receptor
(217) and has been shown to be effective in early phase III
trials of children with systemic JIA despite DMARD and
anti TNF therapy (218). A recent study in a group of chil-
dren with systemic JIA treated with Tocilizumab showed
that growth rate improve significantly following2 years of
therapywith resultant normalization of IGF-1. These chil-
dren however remained relatively short as Ht SDS only
improvedby0.3 SDafter 2 years.Ht SDSat baselinewas
approximately –2.0 SD (219).
5.2 Clinical evidence of growth failure in JIA
Localized growth impairment is not uncommon even in
those with oligoarticular JIA and may result in significant
leg length discrepancy as knees are commonly affected
(194). The temporomandibular joint can also be affected
in those with systemic and poly-articular JIA and may
result in relativemicrognathia, irregular growth of the jaw
(220, 221). Recent 3D facial asymmetry quantification
confirms unilateral destruction of cartilage of the man-
dibular condyle (222) in JIA. All these clinical observa-
tions point to the role of local bone growth impairment
associated with chronic inflammation.
In JIA, poor growth is more common in children with
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poly-articular (especially those with rheumatoid factor
positive) and systemic JIA (207, 223, 224) although ap-
proximately 12%of children with oligoarticular JIA have
recently been shown to have  1SD reduction in Ht SDS
at adult height (AH) compared with Ht SDS at diagnosis
(225). Evaluation of the clinically unaffected knee with
MRI in a group of children with oligoarticular JIA re-
vealed abnormalities in 40% (226). It is possible that clin-
ical evaluation may not be sensitive enough to detect the
more widespread joint involvement in some of these chil-
dren classified as oligoarticular JIA (227). Children with
very earlyonset of systemic JIA (18months) haveamore
severe disease phenotype and unsurprisingly poor growth
is more frequent (228).
Onset of puberty maybe delayed in JIA by about 0.4 to
2.2 years compared to healthy children (229, 230). Pro-
gression through puberty can be compromised in JIA.
None of the adolescents with JIA reached breast and gen-
ital stage5at 16years despite theonset of pubertybetween
12–13 years in one study (230). A few studies have re-
ported thatonsetofpubertymaybe earlier in childrenwith
systemic JIA in comparison with the other subtypes of JIA
(229, 231). These preliminary data need to be interpreted
with care as the onset of puberty was defined by genitalia
stage from patient self-assessment rather than clinical ex-
aminationof testicular volume.Menarche in girlswith JIA
is delayed by one year compared to healthy girls and also
to maternal age of menarche. Age of menarche was sig-
nificantly later in those with systemic JIA in this study
(232). Other studies found no difference for age at men-
arche for girls with JIA (233, 234).
Pubertal growth spurt in JIA may be attenuated and is
often poorest in those with systemic JIA (231). In one
study, actual HVs for children with oligoarticular and
polyarticular JIA were approximately 1.5 cm/ year for
those children aged 12–16 years while HV was only ap-
proximately 0.5 cm/ year for those with systemic JIA. A
substantially compromised magnitude of peak height ve-
locity (2.8 cm/y) was reported in this study. Peak height
velocity was 3.6 cm/y for oligo-articular JIA, 4.9 cm/y for
polyarticular JIA and 1.7 cm/y for systemic JIA (231). HV
for healthy children in puberty ranges from about 4–8
cm/y on average.
Current published studies report significant reduction
in adult height (AH) in JIA (198, 207, 235–239) [Table 1].
However, these studies were published over a decade ago
which would have included children treated in the 1980s.
Theuseof immunomodulators andanticytokinehaveonly
been incorporated into routine clinical practice in the last
10–15 years. Current studies of AH in JIA include differ-
ent numbers of the various subtypes of JIA. The study by
Simon et al from 2002 which reported a mean AH of –2.0
SD only included children with systemic JIA who were
treated for approximately 7 years with continuous oral
GC, a practice that is less common these days even in
childrenwith severe systemic JIA (207). AHof individuals
with JIA treated with contemporary immunomodulators
and anticytokine therapy is currently unknown. In addi-
tion, there is increasing use of intra-articular injection of
GC instead of prolonged use of oral GC which may be
beneficial for controlling joint inflammation but has less
systemic side effects. It is possible that theremaybegrowth
suppressive effects of intra-articular GC especially for
those children who require multiple repeated injections.
Growth and pubertal development in other less com-
mon inflammatory rheumatologic conditions such as sys-
temic lupus erythromatosus (SLE), dermatomyositis, and
systemic sclerosis are not well studied. In a 2 year follow
up study of 331 children with SLE, short stature was un-
common at baseline of study visit (median Ht SDS –0.4,
median parent adjusted Ht SDS –0.3). However, Ht SDS
continued to deteriorate despite institution of therapy,
particularly pronounced in boys. Parents adjusted Ht
SDS  –1.5 was seen in 25% and 15% of males and fe-
males at end of study, respectively (240). In SLE, delayed
onset of puberty was seen in 15.3% of girls (breast stage
Table 1. Published Studies Of Adult Height In Childhood Onset Juvenile Idiopathic Arthritis
No patients
Age at
assessment Adult height result Deviation from mid-parental height
Gare et al. (1995)232 124 (33 oligo, 58 poly, 2 systemic, 30 others) 18 yr Females 165.9 cm, males 176.9 cm ND
Zak et al. (1999)233 65 (21 oligo, 39 poly, 5 systemic) 26 yr Ht SDS  0.3 (11% Ht SDS   2.0) ND
Minden et al. (2002)195 215 (85 oligo, 30 poly, 30 systemic, 30 others) 23 yr Females 166 cm, males 179 cm ND
Packham et al. (2002)236 259 (70 oligo, 78 poly, 52 systemic, 61 others) 28 yr Ht SDS females  1.1 ND
Ht SDS males  0.7
Wang et al. (2002)234 33 (7 oligo, 18 poly, 8 systemic) 20 yr Infrequent GC 165.6 cm Infrequent GC  3.0 cm above MPH
Intermittent GC 165.8 cm Intermittent GC  1.0 cm above MPH
Prolonged GC 147.6 cm Prolonged GC  12.0 cm from MPH
Simon D et al. (2002)204 24 systemic 25 yr Ht SDS  2.0 1.7 SD below MPH SDS (87% below MPH SDS)
41% Ht SDS  2.0
Minden et al. (2009)235 141 JIA 18 ys Females 165 cm, males 176 cm ND
Female poly Ht SDS  0.5
Males poly Ht SDS  0.6
Females systemic Ht SDS  0.5
Males systemic Ht SDS  2.1
JIA: juvenile idiopathic arthritis; Ht: height; cm: centimeter; SDS: standard deviation score; ND: no details; GC: glucocorticoid; MPH: mid-parental height
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2) and 24% of boys (testes  4ml). Over twenty per cent
of adolescent girls with SLE had delayed menarche (15
years) or absent menarche. Irregular menses and second-
ary amenorrheawas seen in fewer than fifty per cent. In the
group of older adolescent girls, delay onset of puberty,
pubertal tempo or menarche was seen in over one third of
girls whereas in older boys, delay onset of puberty and
pubertal tempo was seen in almost fifty per cent (241).
Some studies have reported an association betweenGC
and growth failure in JIA (236, 242)while others have not
(227, 237, 243). One study evaluated the relationship be-
tween inflammatory cytokines and linear growth in 79
children JIA. HV Z score was associated with erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP) and
IL-6. IL-6 was the only significant factor (independent of
other disease markers and GC dose) influencing growth
rate on regression analysis in this study, highlighting once
again the importance of disease itself on growth failure
(244). Although it is often difficult to separate the impact
ofGCand inflammationongrowth impairment, judicious
use of oral GC may have less impact on growth than un-
controlled inflammatory status. However, undoubtedly,
prolonged high dose of systemic GC will have a negative
effect on growth.
To summarize this section, significant growth impair-
ment leading to short stature is often seen in children with
severe poly-articular JIA and systemic JIA. The recent re-
port of long term growth problems in children with oligo-
articular JIA needs to be confirmed in further studies. The
extent of long term growth failure and short stature at AH
in a cohort of individuals with JIA managed with modern
therapies is currently unknown.
5.3 Systemic abnormalities in GH/IGF-1 axis in JIA
Chronic inflammation in JIA is associated with a state
of relative GH resistance. A biochemical picture of GH
resistance was seen in six slowly growing children with
systemic JIA who had normal GH secretion from over-
night GH sampling, normal GH response to two provoc-
ative tests (clonidine and ITT) but low IGF-1 and IGFBP-3
levels (245). Nine out of ten children with JIA underwent
overnight GH sampling had normal GH secretion (246).
Following 4 days treatment with rhGH (0.23 mg/kg/wk),
IGF-1 and IGFBP-3 only increased by 31% and 14% re-
spectively in JIA, while IGF-1 and IGFBP-3 rose by 85%
and73%in8 childrenwith constitutional delay inpuberty
(247). The resistance to GH in JIA is due to a reduction in
GH receptor gene expression. Following a 2 year follow
up period, GH receptor mRNA in lymphocytes of JIA
increased, paralleled by improvement in disease activity,
reduction in IL-6 levels and increase in IGF-1 levels (248)
Impairment of GH secretion is also seen in children
with JIA. Twenty three out of 63 children with JIA who
had been treated with GC for a mean of approximately 4
years at mean 0.2mg/kg/d Prednisolone at evaluation had
evidence of GH deficiency by clonidine and/or arginine
stimulation test (249). In a group of children with JIA not
on oral GC, abnormal GH secretion was diagnosed in
50% based on results of overnight GH sampling and L-
Dopa stimulation test, suggesting that inflammation itself
may also impair GH secretion. The cut off for GH suffi-
ciencywas taken at the level equivalent to 10mcg/L (250).
The recommended peak GH of  10 mcg/L has not been
validated and this arbitrary cut off may need to be altered
with the availability of newer monoclonal GH assays
(251, 252). These may vary depending on the provocative
agent used. However, the clinical studies in JIA mirrors
results experimental studies in animal models of chronic
inflammation induced by lipopolysaccharide and endo-
toxin demonstrating that pituitary derived GH produc-
tion can be reduced (154, 253). The impact of intra-ar-
ticular GC injections onGH secretion in childrenwith JIA
is unknown.
Impairment of IGF binding proteins have also been re-
ported in children with JIA. In 26 children with systemic
JIA, normal levels of ALS, low IGF-1 and markedly low
IGFBP-3 due to increase proteolysis of IGFBP-3 were re-
ported (152). In another study of 17 children with JIA
(majority olio-articular JIA) andmild growth failure, nor-
mal IGF-1, marginally low IGFBP-3 but disproportion-
ately low ALS was reported (254).
While low levels of IGF-1 are generally seen in most
studies of childhood arthritis, some studies suggest that
poorly growing children with inflammatory rheumatic
conditions may have IGF-1 in the normal ranges, which
suggest that a functional state of relative IGF-1 resistance
may exist (246, 255, 256). In 23 children with JIA, mean
IGF-1 SDS adjusted for age was –0.84. Five of those in-
dividuals had relatively “high” IGF-1 SDS1SD (216).
It is possibleGCtreatment in thepresenceof inflammation
reduces IGF-1 sensitivity.A studyof32adultswithRA(16
on Prednisolone) showed that IGF-1 was significantly
higher in the group on Prednisolone (mean 221 g/L vs.
122 g/L). Twelve weeks treatment with anti-TNF ther-
apy (adalimumab) led tonormalizationof the raised IGF-1
in the group on Prednisolone such that the levels were
similar in both groups (256).
To summarize this section, studies of the systemic GH-
IGF axis in children with JIA point to a state of GH re-
sistance in most the cases. Abnormalities in GH secretion
may also exist in non-GC treated children, although this
could be due to the impact of intra-articular GC. Abnor-
malities of IGF binding proteins are reported in children
with JIAbut comprehensive studiesof the ternary complex
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are still currently unavailable. IGF-1 resistance especially
in those treated with high dose GCmay also occur. While
GH/IGF-1 resistance occurs in JIA, there is insufficient
scientific evidence to determine the contribution of sys-
temic hormone resistance on growth impairment in chil-
dren with JIA.
5.4 Efficacy of rhGH on linear growth in JIA
Earlier nonrandomized studies that included children
with JIA who were relatively older reported that HV can
improve by over 100%with rhGH (247, 257–264) [Table
2]. Subsequent randomized controlled trials including one
with a placebo arm have confirmed these findings and
suggest a modest effect on short to medium term catch-up
growth [Table 3] (39, 250, 265–268)
Two studies that compared different doses of rhGH
suggested better growth response with the “higher” dose
compared with the “lower dose” (0.16mg/kg/wk vs. 0.33
mg/kg/wk and 0.15 mg/kg/wk vs. 0.30 mg/kg/wk) (247,
260). A recent trial in JIA has investigated even higher
doses of rhGH (0.47 mg/kg/wk) (268). The growth re-
sponse appears to be better in this study but the subjects in
this trial had shorter durationof disease andGCexposure.
The only randomized study with AH data in chronic
inflammatory disease was conducted as an RCT using
rhGH0.33mg/kg/wk for ameandurationof 8.4 years and
it reportedameandifferenceof14.3 cmatAHbetween the
two groups. Treatment led to a net gain ofHt SDS of2.3
SD as the control group lost 0.7 SD from baseline to AH.
At AH, rhGH treated patients were still relatively short
with mean AH of –1.6 SDS. However, untreated children
had a mean AH of –3.4 SDS (39) [Figure 8]. The efficacy
of rhGH on AH in JIA is similar to gains seen in children
with chronic renal insufficiency (CRI) treated with rhGH
(269, 270).
In a nonrandomized study using rhGH0.33mg/kg/wk,
using data from some of the children previously included
in a randomized trial and patients clinically treated with
rhGHoff label,mean total pubertal height gainwas7.3 cm
better with rhGH treatment. Similarly, mean AH in the
rhGH group was – 1.7 SD while the AH of the matched
controls was –3.2 SD (249). Total pubertal growth with
rhGH in JIA is comparable to childrenwith idiopathicGH
deficiency treated with rhGH and healthy children during
puberty (249, 271, 272).
To evaluate the role of “early” use of rhGH before
significant short stature is present, Simon et al conducted
an RCT using rhGH 0.47 mg/kg/wk in a group of prepu-
bertal children with JIA who were growing at less than
3cm/y and had a mean Ht SDS of about –1.0. These chil-
dren had a relatively short duration of disease of approx-
imately 2 years at baseline. After 3 years of rhGH, the
relative Ht gain was 1.5 SD (268). These data suggest
that early introduction of rhGH in the course of JIAbefore
the onset of severe growth impairment may normalize
growth rate. The benefit of “early” treatment with rhGH
before the onset of severe growth failure needs further
evaluation particularly in light of newer therapeutic de-
velopment in JIA diseasemanagement, althoughwe know
that catch-up growth following anticytokine therapymay
only be modest (22).
There is now sufficient evidence to show that the use of
relatively high dose rhGH leads to improvement of linear
growth in children with JIA. Only one study with infor-
mation on AH using rhGH dose similar to those used in
conditions like TS and CRI report fairly similar AH out-
come. Larger, adequately powered trials of rhGH in JIA
are now needed to confirm long term AH outcome and
address issues like optimal dose of rhGH and timing of
starting rhGH.The impact of rhGH in thosewith systemic
JIA, often the ones most severely affected, is still unclear,
as current trials have included only a small number of such
children. Future rhGH studies will also need to stratify for
JIA subtypes at inclusion.
5.5 Factors affecting the growth response to rhGH in JIA
5.5.1 Disease status and glucocorticoid
Studies of rhGH in JIA have demonstrated that the
growth response to rhGH is negatively associated with
Table 2. Published Non Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In



















Butenandt et al. (1979)256 Retrospective 20 Variable 0.18 13.0 2.7 6.2 (1st yr) 130% - - -
Svantesson et al. (1991)259 Retrospective 6 Variable 0.16–0.46 13.7 2.8 6.7 (1st yr) 139% 3.4 - -
Davies et al. (1994)257 (1997)244 Prospective 10 low dose 1.0 0.15 9.2 2.4 4.5 88% 3.0 - -
10 high dose 0.30 10.6 2.0 6.1 205% 3.4
Touati et al. (1998)260 Prospective 14 1.0 0.46 10.8 1.9 5.4 184% 4.3 4.3 0
Al-Mutair et al. (2000)254 Retrospective 10 Variable 0.16–0.30 11.9 2.5 4.8 (1st yr) 92% - - -
5.4 (2nd yr) 116%
Simon et al. (2003)258 Prospective 14 3.0 0.46 12.5 2.0 6.0 (1st yr) 200% 4.6 4.5 (1st yr) 0.1
5.0 (2nd yr) 150% 4.3 (2nd yr) 0.3
4.1 (3rd yr 105% 4.3 (3r yr) 0.3
Bechtold et al. (2004)255 Prospective 11 4.0 0.25–0.33 10.3 - - - 3.9 2.1 1.8
yrs; years; rhGH: recombinant hman growth hormone; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation
score
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inflammatory markers such as CRP (39, 260) and ESR
(39). Some studies also found a negative association be-
tween cumulative prednisolone dose and growth rate dur-
ing rhGH therapy (255, 261, 265, 266). The association
between prednisolone dose and growth rate was not sta-
tistically significant when the analysis was performed in a
regression model, suggesting that inflammation plays a
greater role in modulating growth response (39). One
study showed that children with polyarticular JIA grew
better on rhGH than those with systemic JIA although the
number of children with systemic JIA was relatively small
(263)
5.5.2 Systemic IGF-1 levels
A modest positive association has been reported be-
tween growth rate with IGF-1 and IGFBP-3 in response to
rhGH. AH of the rhGH and control patients in the study
by Bechtold et al showed a modest association with aver-
age IGF-1 and IGFBP-3 in JIA (r  0.61 for IGF-1 and
IGFBP-3) over the treatment period (39).
5.6 Efficacy of rhGH on disease process in JIA
There are no published studies of rhGHon its effects on
experimental arthritis, but there is currentlynoevidence to
Table 3. Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children
With Juvenile Idiopathic Arthritis

















Bechtold et al. (2001)266 RCT 14 rhGH 2.0 0.33 9.7 2.9 SD 0.3 SD - 3.7 2.9 0.8
5 rhGH (GHD) 0.16 10.5 3.1 SD 0.5 SD 2.6 2.4 0.2
16 Ctrl 7.8 3.2 D 1.2 SD 2.9 3.2 0.3
Bechtold et al. (2003)265 RCT 18 rhGH (9GHD) 4.0 0.33 (0.20 for GHD) 10.5 2.4 cm/yr 4.7 cm/yr 96% 3.3 2.3 1.0
20 Ctrl 9.6 2.3 cm/yr 3.4 cm/yr 48% 2.3 3.0 0.7
Saha et al. (2004)250 RCT (Cross-over trial rhGH vs. placebo) 24 0.5 0.23 9.0 - 2.0 SD (rhGH) - 2.1 1.9 0.2
0.1 SD (placebo) 2.2 2.0 0.2
Grote et al. (2006)267 RCT 10 rhGH 2.0 0.32 8.0 - - - 1.4 1.0 0.4
7 Ctrl 8.1 1.9 2.1 0.2
Simon et al. (2007)268 RCT 15 rhGH 3.0 0.47 5.6 2.7 cm/yr 6.5 cm/yr 141% 1.1 0.4 0.7
15 Ctrl 5.7 2.6 cm/yr 5.0 cm/yr 85% 1.0 1.8 0.8
Bechtold et al. (2007)39 RCT 13 rhGH 13.7 0.33 4.8 2.2 SD - - 2.7 1.6 1.1
18 Ctrl 14.4 4.0 2.6 SD 3.5 3.4 0.1
RCT: randomized controlled trials; yrs; years; rhGH: recombinant hman growth hormone; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity;
Ht: height; SDS: standard deviation score
Figure 8.
Height SDS In Children And Adolescent With IBD And Body Image Domain Score On IMPACT III Questionnaire (Mason A et al Horm Res Pediatr
2014; 83:45–54)
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suggest any specific concerns about worsening of inflam-
matory arthritis.
6. Inflammatory bowel disease (IBD)
6.1 Disease and management
Inflammatorybowel disease is a groupof inflammatory
disordersof thegastrointestinal (GI) tract characterizedby
chronic inflammation. IBD has a relapsing and remitting
nature, which is often unpredictable. IBD has classically
been categorized into ulcerative colitis (UC) and Crohn’s
disease (CD) on the basis of combinations of clinical pre-
sentation, radiological and endoscopic and histopatho-
logical features. Recent evidence suggests that the under-
lying etiology of IBD is due to the interaction of three
factors: genetic susceptibility, environment abnormal im-
mune host response and commensal gutmicrobiota (273).
It is believed that the pathogenesis of IBD occurs from
errors in the interpretation or regulation of immune per-
ception and responsiveness to endogenousmicrobiota and
thus disruption inmucosal homeostasis. This results in the
initiation of immune responses in genetically predisposed
individuals (274). Familial aggregation of IBD has long
been recognized (275–278), but in the last twenty years
detailed mapping of a region on chromosome 16 resulted
in the identification of the NOD2/CARD15 gene. This
gene encodes a cytoplasmic protein designated NOD2 or
CARD15, which serves as a pattern recognition receptor
for bacterial lipopolysaccharide and regulates activation
of nuclear factor-k and secretion of a-defensins by ileal
paneth cells (279–281). Numerous other candidate genes
have subsequently been identified but only accounts for a
small proportion of pediatric IBD (282–284).
Focusing specifically on growth and genetic influences
in pediatric IBD, studies have shown that patients with an
OCTN1/2 haplotype (285) and those with the IL6–174
GGgenotypehad lowerheight atdiagnosis (161).Another
study revealed that patients with TNF- promoter poly-
morphism had higher Ht SDS at diagnosis (286). A much
more recent study reported significant association be-
tween growth impairment in CD and a stature related
polymorphism in the dymeclin gene (287). To date, it is
unclear if these associations with genetic factors are inde-
pendent of the severity of inflammation
6.1.1 Ulcerative colitis
UC is a conditionwhere the inflammatory response and
morphologic changes remain confined to the large intes-
tine,with rectal involvement inabout95%of cases. InUC,
inflammation is limited to themucosa and consists of con-
tinuous involvement of variable severity, with ulceration,
edema and hemorrhage along the length of the colon.
Characteristic histopathological findings are chronic mu-
cosal inflammationwith extensivepolymorphnuclear leu-
kocytes, mononuclear cells, crypt abscesses, and distor-
tion of mucosal goblet glands and goblet cells. Induction
of remission at diagnosis and subsequent acute relapse is
with oral GC. Maintenance of remission in UC is with
background therapies like amino salicylates (mild disease)
or immunomodulators (eg, azathioprine, methotrexate)
and anticytokine disease. In UC, major surgery with total
colectomy and ileal pouch anal anastomosis is curative
(288). The efficacy of anticytokine therapy in UC is un-
clear and as such not used as frequently (289).
6.1.2 Crohn’s disease
In contrast, CD is inflammation that can involve any
part of the GI tract from the oropharynx to the perianal
area. Diseased and inflamed segments are separated by
normal healthy bowel otherwise known as “skip lesions”.
Inflammation can be transmural, often extending to the
serosa, resulting in sinus tracts or fistula formation. Typ-
ical histopathological findings include small superficial
ulcerations over a Peyer’s patch and focal chronic inflam-
mation extending to the submucosa and sometimes ac-
companied by non caseating granuloma formation. Com-
mon sites involved are the ileocecal region, terminal ileum,
small bowel and isolated colonic involvement.
In CD, induction of remission of mild to moderate dis-
ease is often with exclusive enteral nutrition (EEN) (290).
This is the provision of an exclusive liquid diet for a du-
ration of 8–12 weeks which has been shown to be just as
effective as GC for reduction of inflammation and but has
no adverse effects on growth and bone metabolism (291).
EEN is commonly used in Europe and is gaining popular-
ity in the United States and the rest of the world. Back-
ground maintenance therapy using amino salicylates or
immunomodulators with azathioprine are often used in
moderate to severe disease close to the time of diagnosis.
Methotrexate can be used as a second line immunomodu-
latory (292).
Escalation to anticytokine therapy like infliximab and
adalimumab will be considered in those children with se-
vere disease who are not responsive to GC and those with
chronic low grade inflammation but who are GC depen-
dent. In the realworld setting, the use of anti-TNF therapy
in pediatric CD is associated with modest response with
56% achieving remission after 12 months (293). Safety
issues like significant acute reactions and long term safety
concerns including lethal forms of lymphoma preclude its
use over extended periods of time (294, 295). There is no
doubt that the use of anti-TNF therapy inCD is associated
with improvement in linear growth (296–298). Similar to
the experience in children with JIA, this improvement is
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only modest with studies reporting increased inHt SDS of
between 0.2 to 0.3 SD over 12 months of therapy (299).
6.1.3 Inflammatory bowel disease unclassified
CD involving the colon only is commoner is children
than in adults which makes it challenging to distinguish
CD and UC for some individuals. In these instances, the
term IBDunspecified (IBDU) is used (previously known as
indeterminate colitis). Observational studies suggest that
childrenwith IBDU could be considered a distinct subtype
of IBD as the disease often takes an aggressive and pro-
gressive course (300)(REF).
6.2 Growth failure in children with IBD
In IBD, growth impairment appears to be more fre-
quent and severe in children with CD than those with UC
(18, 301, 302) (303, 304).AUK IBDregister that collected
data for new cases presenting between 1997 and 2003,
reported that, at diagnosis, mean Ht SDS was –0.3 for
both boys and girls with CD whereas it was –0.1 and
0.22 for boys and girls with UC, respectively (305). Ht
SDS  –2.0 is present in approximately 10% of children
with CD at diagnosis (18, 306, 307). In another recent
study, mean Ht SDS for 102 children with CD (mean age
11.9 years) was –0.2, but those with Saccharomyces
cerevisiae antibody (ASCA) had significantly lower height
that those without (308). While height reduction at diag-
nosis as a group appears to be mild, deteriorating height
velocity is known to occur before the diagnosis of CD and
can occur in the absence of GI symptoms (309). A retro-
spective study of 116 children with CD provided further
evidence for this as these children were shorter than their
genetic potential at diagnosis with mean Ht SDS of –0.5
compared with midparental Ht SDS 0.2 (18).
Several contemporary studies show that despite mod-
ern therapies, growth failure and short stature is still seen
in a subset of children and adolescents with IBD (18, 307,
310). A study in a cohort of contemporary children and
adolescents with IBD showed that Ht SDS showed a neg-
ative association with the body image domain of the pe-
diatric IBD specific QOL score IMPACT III, with higher
scores indicating poorer QOL (10) [Figure 8]. Further re-
search on the impact of abnormal growth and pubertal
development and the impact onQOL in childrenwith IBD
and other groups of chronic disease are needed. This is a
challenging area to acquire meaningful information as
there needs to be distinction between the impact of poor
growth and the impact of the disease itself on QOL.
Delayed onset of puberty has been previously reported
to be common in CD (6, 311–313), although careful eval-
uation of pubertal status by clinician examination is cur-
rently limited (10, 311). Other current published studies
have used age of menarche, bone age delay and age at
initiation of growth spurt as assessment of pubertal delay
(6, 312–314). A report from the mid-90s showed that on-
set of breast development was delayed by 1.5 years in
childrenwithCDandUC. Boys in that study had 0.8 years
delay in onset of testicular enlargement consistent with
early puberty. This report is from a time when immuno-
modulators and certainly biologic therapywould not been
used in clinical practice with heavy reliance on long term
oral GC therapy.
Although the treatment of children with IBD has
changed considerably, a study from a contemporary co-
hort of children who analyzed retrospective pubertal
growth data reported persisting evidence of delayed pu-
berty as judged by the age at peak height velocity in those
withCD. This delaywasmore likely in thosewith a higher
ESRor lowerBMI. PeakHVSDSadjusted for pubertal age
was also reduced, suggesting that the pubertal growth
spurt may be attenuated. This study however, excluded
children whowere treated clinically with growth promot-
ing therapy like sex steroid and / or rhGH, who by default
are likely to be those with significant short stature or se-
vere growth retardation (6). Therefore it is possible that
there is greater impact on puberty and pubertal growth
spurt despite modern therapy. A recent prospective study
of a cohort of children and adolescents with IBD suggests
that pubertal delay was uncommonwith only 0.3 years of
bone age delay. Adolescent boys had attenuated growth
rate during puberty whereas marginally delayed onset of
puberty was seen in adolescent girls with IBD in this con-
temporary cohort (10).
Two studies demonstrated bone age delay of approxi-
mately one year in children with CD (312, 313, 315),
which is within acceptable limits, including one study
from patients managed between 2007–2009 with 60% of
patients on immunomodulators and 20% on infliximab
(315) In girls, age at menarche occurred after 16 years in
73% with CD in a cohort managed between 1968 and
1983 (314). In a cohort managed between 2007–2009,
girls with CD reached menarche at median age of 13.9
years (313)compared with healthy controls of 12 years.
Several contemporary studies of growth in children
with IBD show lack of adequate catch up growth despite
advances in primary disease therapy. In a study of 176
children with CD, Ht SDS at diagnosis, 1 and 2 years
remain unchanged at approximately –0.5 SD. The per-
centage of children with Ht SDS  –2.0 however was
slightly less frequent by 2 years: 10% at diagnosis, 8% 1
year, 6.5% 2 year. This cohort was largely managed with
oral GC (Prednisolone) for induction of remission as only
4% had primary enteral nutrition therapy within 3
months of diagnosis (306). Another study of 116 children
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with CD where enteral nutrition was more commonly
used for induction of remission (63% of cases from diag-
nosis), Ht SDS (approximately –0.5 SD) remained the
same fromdiagnosis to amean final follow-up of 4.6 years
after diagnosis (18).
In contrast to JIA, only a modest reduction in AH has
been reported by most studies in adults with childhood-
onset IBD (3, 8, 9, 303, 314, 316–319) [Table 4]. AH is
significantly lower in childhood onset CD with onset be-
fore puberty, although definition of puberty in this study
was unclear (320). In a relatively contemporary cohort of
123 patients with CD, AH was only 2.4 cm lower than
target height. However almost twenty per cent achieved a
AH that was more than 8cm below their midparental
height suggesting that a small subgroup of adults with
childhood onset CD may have significant long term
growth impairment leading to short stature. Longer du-
ration of symptoms prior to diagnosis and jejunal disease
were related to AH in that study but these factors require
further study (9). Conventional assessments with endos-
copy and barium studies often do not identify jejunal dis-
ease adequately, questioning the relationship with AH in
that study. Parents’ heights were also obtained from pa-
tient estimation. In another study of AH in IBDwhere 108
patients had AH and parental height measurements per-
formedby researchers, 28outof 108 (26%)whohadmore
than oneHt SDS –1.6 during growth (defined as growth
impaired group) had AH of 0.9 SD lower than midparen-
tal Ht SDS. In those with no evidence of growth impair-
ment, defined as those who did not have Ht SDS  –1.6
more than once during growth, AHwas only 0.1 SD lower
than midparental Ht SDS (319).
Published evidence suggests that short term linear
growth may be better in those children managed with en-
teral nutrition during acute relapse compared with oral
GC (321, 322), although the effects of EEN practice on
long term growth outcome is less convincing. AH in CD
(-0.4 SD) did not differ between an American study (319)
and aUnitedKingdom study (-0.3 SD) (9) where the agent
of induction of remission differed: oral GC in the Amer-
ican study and EEN in the United Kingdom study. Simi-
larly, in a group of children with CD managed with EEN
at initial diagnosis and who were encouraged to continue
to take supplemental enteral nutrition, weight and BMI
SDS increased up to 2 years follow-up, whereas Ht SDS
remained unchanged (323).
Numerous studies of anticytokine therapy using inflix-
imab and adalimumab in CD show significant improve-
ment in growth rate (296–298), although some did not
demonstrate any improvement in linear growth (324,
325).The improvement in growth in these childrenmaybe
independent of progression in puberty, reduction in GC,
and maybe better in those who are concurrently treated
withmethotrexate.However approximately 30%of these
children may still have poor growth following biologic
therapy (296).
Clinical studies in children with IBD have largely
shown no relationship between GC and linear growth
(304, 326). Saha et al, reportednodifference inHt andHV
SDS in prepubertal children with CD and UC treated with
GC vs those who did not receive GC (243). A more recent
study of a cohort of 102 children with CD treated with
long term low dose oral GC in the form of Prednisolone
(mean dose of 0.2mg/kg/d formean 14.4months) showed
that almost twenty per cent of the cohort showed growth
failure, although HV was not adjusted for delayed pu-
berty.Of thosewith growth failure, only one third showed
catch up growth after discontinuation of GC (327).
Several studies have evaluated the association between
cytokines with linear growth and markers of the GH-IGF
Table 4. Published Studies Of Adult Height In Childhood Onset Inflammatory Bowel Disease
No patients
Age at
assessment Adult height result
Deviation from
mid-parental height
Castile et al. (1980)316 177 CD 23 yr Medically managed Ht SDS  0.6 ND
Surgically managed Ht SDS  0.3
Griffiths et al. (1993)3 67 CD 17 yr and HV  1 cm/yr Females Ht SDS  0.5 ND
Males Ht SDS  1.0
Markowitz et al. (1993)317 48 IBD (38 CD, 10 UC) 21 yr CD: 56%  25th centile ND
UC: 25%  5th centile
Hildebrand et al. (1994)303 124 IBD (46 CD, 60 UC18 IBDU) 16 yr or HV 0.5 cm/yr CD Ht SDS  0.4 ND
UC Ht SDS  0.2
IBDU Ht SDS  0.1
Ferguson et al. (1994)314 70 IBD (50 CD, 20 UC) ND CD males 175 cm, CD females 157 cm ND
UC males 175 cm, UC females 159 cm
Alemazedeh et al. (2002)318 135 CD  18 yr Prepubertal onset Ht SDS  1.0 Prepubertal onset 2.1 cm below MPH
Pubertal onset  0.1 Pubertal onset 0.6 cm above MPH
Adult onset  0.1 Adult onset 0.9 cm above MPH
Sawczenko et al. (2003)8 43 CD 16 yr Ht SDS  0.7 5.9 cm below MPH
Sawczenko et al. (2006)9 123 CD HV  1 cm/yr Ht SDS  0.3 3 cm below MPH but 20% were  8 cm below MPH
Lee et al. (2010)319 141 IBD  18 yr “Growth impaired” Ht SDS  1.3 “Growth impaired” 0.7 SD lower than MPH SDS
“Not growth impaired” Ht SDS  0.1 “Not growth impaired” 0.1 SD lower than MPH SDS
IBD: inflammatory bowel disease; CD: crohn’s disease; UC: ulcerative colitis; IBDU: inflammatory bowel disease unclassified; Ht: height; cm: centimeter; SDS: standard
deviation score; ND: no details; MPH: mid-parental height
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axis in childrenwith IBD. In37childrenwith IBD(17CD),
IGF-1 levels were lower while IGFBP-2 was higher com-
pared with controls during relapse. IL1- levels were re-
lated to negatively with IGF-1 and positively with
IGFBP-2 (328). Levels of lipopolysaccharide was signifi-
cantly higher in children with CD lower height at diagno-
sis and follow-up (329). Several studies of genetic poly-
morphism in genes regulating cytokine production have
shown a relationshipwith growth impairment in pediatric
IBD. Children with CDwith the –174 GG promoter poly-
morphism which affects IL-6 transcription had signifi-
cantly lower Ht SDS at diagnosis (161). The presence of
238G/A and 863C/A polymorphism on the TNF- pro-
moter gene has been shown to be associated with better
height and linear growth in children with CD and appears
to be independent of disease activity (286).
Current studies suggest that a subgroup of children
with IBDespecially thosewithCDhave significant growth
failure leading to short stature at AH. Despite the intro-
duction of modern GC sparing therapies including anti-
cytokine therapies, poor growth is still encountered, al-
though significantly delay in onset of puberty is perhaps
less common. The authors believe that the persistence of
poor growth in a small group of these children reflect the
fact that some childrenwithCDstill donot achieve disease
remission with current therapies or adverse effects pre-
clude the use of aggressive modern therapies. Given the
shortwindow for growth inCD, as the age of presentation
is often in the adolescent years, adjuvant growth promot-
ing therapies may still need to be explored in this small
subset. Finally, the growthoutcomeof childrenwith IBDU
who may have a more severe disease course is still cur-
rently unclear.
6.3 Systemic abnormalities in the GH/IGF-1 axis in
children with IBD
Similar to children with JIA, growth failure in IBD is
associated with a state of GH resistance. Early evaluation
of the GH axis in 10 children with IBD showed excessive
rather than impaired response, using overnight GH pro-
file, propranolol-glucagonand ITT, supporting thenotion
that these childrenmaybeGHresistant (330). IGF-1 levels
have been shown to be low in these children, although
again delayed maturation may contribute to these result
(331). Similarly, in 14 children with CD and growth fail-
urewhowere not on oral GC, normalGH response to ITT
was seen in most of the children. Four out of 14 (29%) of
these children had peak GH levels  6 mcg/L suggesting
abnormalities in GH secretion (332). In a study of 5 chil-
drenwith CDwith poor growth and delayed puberty (me-
dian age 15 years,median bone age 11 years and all except
one patient was in Tanner I and II), three out of the 5 had
inadequate five hourmeanGH levels and peakGHduring
sleep-further evidence that subtle abnormalities in GH se-
cretion may exist. However, only one child had low GH
peak to ITT and none of these 5 children were on oral GC
(333).
Abnormalities in the GH axis may be present at diag-
nosis of children with IBD (330). In addition, abnormal-
ities in the GH-IGF axis in children with chronic inflam-
mation are not permanent as they have been shown to be
responsive to primary disease therapeutic intervention us-
ing Prednisolone (334), enteral nutrition (335, 336), inf-
liximab (337) and surgical resection (336).
It is nowrecognized that a rangeof abnormalities inGH
and IGF-1 secretion and sensitivity exists in children with
IBD and growth failure (338) [Figure 9]. In 28 children
with IBD (25 CD) evaluated with an ITT, 11 (39%) had
peak GH  6 mcg/L and IGF-1 SDS  0 (biochemical
functionalGHresistance). Biochemical functionalGHde-
ficiency defined as peak GH 3 mcg/L and IGF-1 SDS
0 was seen in 4 (14%). Biochemical functional GH insuf-
ficiency defined as peakGH 6mcg/L but 3mcg/L and
IGF-1 SDS  0 was seen in 11 (39%). Two children had
normal GH levels and IGF-1 SDS  0 suggestive of bio-
chemical functional IGF-1 resistance.
Comprehensive studies of the IGF binding protein and
ternary complex in children with IBD are currently not
available. In a contemporary group of children and ado-
lescents with IBD, pubertal onset was not delayed but ab-
normal pubertal growth was observed. This was associ-
atedwith reduction in IGF-1 levels butmarginally elevated
IGFBP-3, which was postulated to lead to reduction in
bioavailability of free IGF-1 (10). A recent study reported
gender differences in IGF-1 and IGFBP-3 levels in children
with CD such that boys had significantly lower levels even
after adjusting for bone age delay, although Ht SDS was
similar in both groups (315). A previous study suggested
that females with CD had a more severe disease course,
althoughmales were more likely to exhibit growth failure
(339). One study previously reported that IGFBP-2 is sig-
nificantly higher in children with CD at relapse and that
this was associated with IL-6 (328). The role of IGFBP-2
and regulation of linear growth is unclear but it is thought
that it may lead to reduction of the formation of ternary
complex and may have a direct inhibitory role at the level
of the growth plate (340, 341).
In summary, growth failure in children with IBD is as-
sociatedwith a range in defects in secretion and sensitivity
of the GH-IGF1 axis. The relative contribution of inflam-
mation, use of GC and nutrition on these systemic abnor-
malities is difficult to tease out from current studies. In-
deed, the contribution of these systemic abnormalities on
the growth phenotype of these children is unclear. Studies
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with comprehensive evaluation of IGF binding proteins
are limited in childrenwith IBD. IGFBP-2maybe amarker
of disease in childrenwith IBDbutwhether IGFBP-2 plays
an inhibitory role on linear growth in childhood IBD is still
unknown.
6.4 Efficacy of rhGH on linear growth in IBD
Compared to studies in JIA, there is a paucity of data of
rhGH in children with IBD [Table 5 (342–348) and Table
6 (349–351)]. A nonrandomized study of rhGH (0.35mg/
kg/wk) in 10 children (Mean age 11.9 yrs, Ht SDS of –1.8)
reported an 85% increase in HV at 6 months rising from
4.0 cm/yr. to 7.4 cm/yr. This improvement was main-
tained in a subgroup of seven children who continued
treatment for a further 6 months (344). The only RCT of
rhGH at 0.45 mg/kg/wk, for improving linear growth in
children with IBD, conducted byWong et al reported that
HV increased by a median of 140% in the rhGH group
comparedwith an8%reduction in the control groupat six
months [Figure 10]. Therapy over the six months period
was associated with a median difference of 3.3 cm of
height gain between the rhGH and control group; equiv-
alent to a median relative gain in height SDS of 0.4SD
(351). rhGH therapy in this trial was associated with sig-
nificantly higher levels of total IGF1, but no significant
changes in IGFBP-3, ALS, free IGF-1 and IGFBP-2 (352).
Another RCT of rhGH (0.53 mg/kg/wk) in children with
CD designed to evaluate the role of rhGH in improving
disease process, showed that HV improved by 60% in the
rhGH group at 12weeks. Eighteen of the 20 children who
showed disease clinical remission at 12 weeks continued
rhGH for a total of 52 weeks. Ht SDS of this group im-
proved from –1.1 to –0.4 (350).
Given the results of the preliminary studies of rhGH in
children with IBD, there now needs to be larger definitive
trials of rhGH in slowly growing children. Challenges in-
clude interpretation of growth rate during puberty and
evaluation of disease activity. It is possible that the growth
response to rhGH may be more favorable in those with
shorter duration of disease and where nutrition is opti-
mized. In that regard, future clinical trials of rhGH in IBD
should target those with shorter duration of disease since
diagnosis and explore the benefit of concurrent supple-
mental feeding.
6.5 Factors affecting the growth response to rhGH in
IBD
6.5.1 Disease and glucocorticoid
In IBD, HV was inversely related
to pediatric crohn’s disease activity
index (PCDAI) and ESR. However,
in individuals on rhGH but not the
control group,HVshowedapositive
association with hemoglobin, nega-
tive associations with ESR and PC-
DAI. Cumulative prednisolone dose
was not associated with growth re-
sponse but the dose of prednisolone
used in that cohort was negligible
(351).
6.5.2 Systemic IGF-1
In children with IBD treated with
rhGH, IGF-1 showed a modest but
weak statistically significant associ-
ationwith growth rate during the pe-
riod of treatment (351).
6.6 Efficacy of rhGH in on disease
process in IBD
Several animal models of colitis
suggest a direct effect of rhGH on
chronic inflammation via a reduc-
tion of both mucosal apoptosis and
IL-6 dependent signal transducer
and activator of transcription3
Figure 9.
Peak Growth Hormone (GH) and Insulin-Like Growth factor 1 (IGF1) To Insulin Tolerance Test
(ITT) In Children With Inflammatory Bowel Disease (IBD).
IGF1: insulin-like growth factor 1, GH: GH, SDS: standard deviation score.
Grp A: Peak GH  3 mcg/l, IGF1 SDS  0 (Functional GH deficiency).
Grp B: Peak GH  6 mcg/l but  3 mcg/l, IGF1 SDS  0 (Functional GH insufficiency).
Grp C: Peak GH  6 mcg/l, IGF1 SDS  0 (Functional GH resistance).
Grp D: IGF1 SDS  0 (Functional GH-IGF1 resistance).
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(STAT3) activation (173, 174, 353). rhGH can also di-
rectly alter systemic markers of inflammation. rhGH in
childrenwithGHdeficiency (GHD)may lead to reduction
in systemic proinflammatory cytokines although the data
of rhGH in children with non-GHD states are conflicting
(354–358). In a studyby Slonimet alwith the primary aim
of assessing the effects of rhGH treatment on reduction of
inflammation, 32 adults with CD were randomized to
rhGH (17 rhGH) or placebo injections for four months.
rhGH treatment was administered at 5 mg daily for one
week followed by 1.5 mg daily thereafter. Reduction in
Crohn’s disease activity index (CDAI) was significantly
greater at 4 months with rhGH: –143 points in the rhGH
group and –19 in the placebo group. There was however
no significant change in Hb, hematocrit (HCT), ESR, pre-
albumin, ferritin or iron levels after 4 months (347).
To explore the role of rhGH on disease activity in pe-
diatric CD,Denson et al conducted anRCT in 20 children
(19 rhGH) with CD (10 rhGH-0.53 mg/kg/wk). The au-
thors’ concluded that rhGH may be an adjunct for treat-
ment of inflammatory disease based on improvement in
PCDAI (350). In the rhGH group, PCDAI was 32 and 8
points at baseline and 12 weeks. In the control group,
PCDAI was 33 and 22 at baseline and 12 weeks. The
percentage of GC usage in the rhGH group was lower at
12 weeks, although the dose of prednisolone was similar
inbothgroups.Othermarkersofdisease activity including
endoscopic severity, fecal calprotectin and ESR were also
similar.
While generally accepted and validated as a disease in-
dex, there is a potential pitfall in the use of PCDAI (359)
in rhGH studies. PCDAI is made up of three domains:
(1) Subjective patient recall of symptoms
(2) Laboratory parameters and clinical examination
(3) Auxology: weight and HV SDS. HV SDS accounts
for 10 points if HV SDS –2.0 SD, 5 points if –1.0 SD
but  –2.0 SD and 0 points if HV SDS  –1.0.
In the study byDenson et al,HVSDSwas –1.0 and –1.8
at baseline in the rhGH and control group. At 12 weeks,
HVSDSwas2.0and–2.1 in the rhGHandcontrol group
(350).Webelieve that the lowerPCDAI in the rhGHgroup
in that studymerely reflects improvement in linear growth
independent of reduction of inflammation. The possibility
that rhGHmay improve inflammationdirectly inpediatric
CD remains an open question but need to be explored in
future studies using other disease endpoints other than the
PCDAI.
In the study by Wong et al PCDAI was lower after 6
months therapy with rhGHwhich could be interpreted as
improvement in disease activity.However, when datawas
analyzed using the abbreviated PCDAI which omits the
laboratory, physical examination and auxology domains,
there was no difference in disease activity over the 6
months in both groups. ESR, CRP, Hb, HCT, albumin,
TNF, IL-1 and IL-6 were similar in both groups and after
the 6 months period (351). Extensive evaluation of 28
cytokines, chemokines and inflammatory growth factor
using the Multiplex assay in that clinical trial showed no
differences over the six months period in rhGH or control
group and they also did not differ between the two groups
Table 5. Published Non-Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In



















McCaffery et al. (1974)342 Retrospective 2 0.5 10 mg for 5 days then 3 mg three times per week - 6.5 cm/yr 9.2 cm/yr 42% - - -
Henker et al. (1996)343 Retrospective 3 2.0 0.9–1.0 mg daily 16.2 5.0 cm/yr 10.4 cm/yr 108% 3.4 1.6 1.8
Mauras et al. (2002)344 Prospective 10 0.5–1.0 0.35 11.9 4.0 cm/yr 7.4 cm/yr (1st yr) 85% - - -
Wong et al. (2007)345 Retrospective 7 Variable 0.15–0.31 15.9 2.5 cm/yr 3.7 cm/yr (0.5 yr) 48% 2.2 1.9 0.3
Heyman et al. (2008)346 Prospective 8 rhGH 1.0 0.30 12.6 3.0 cm/yr 8.3 cm/yr 177% 2.0 1.2 0.8
24 historical Ctrl 12.5 4.0 cm/yr 4.9 cm/yr 23% 1.8 1.6 0.2
Slonim et al. (2009)348 Retrospective 4 4.5–7.5 0.18–0.20 13.8 - - - 3.5 1.9 1.6
yrs; years; rhGH: recombinant human growth hormone; Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS:
standard deviation score
Table 6. Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children
With Inflammatory Bowel Disease



















Calenda et al. (2005)349 RCT (Placebo cross-over) 3 rhGH 1.0 0.35 11.0 - - - - - 0.1 SD
4 Ctrl (placebo) 0.2 SD
Denson et al. (2010)350 RCT 10 rhGH 0.25 0.53 12.0 - 2.0 SD - - - -
10 Ctrl 13.0 2.1 SD
Wong et al. (2011)351 RCT 11 rhGH 0.5 0.45 14.7 4.5 cm/yr 10.8 cm/yr 140% 2.8 2.5 0.3
11 Ctrl 13.7 3.8 cm/yr 3.5 cm/yr 7.9% 1.8 1.9 0.1
RCT: randomized controlled trial; yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV:
height velocity; Ht: height; SDS: standard deviation score; SD: standard deviation
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(352). Careful disease evaluation including the use of fecal
calprotectin, endoscopy or new imaging techniques like
MRI should be considered in future rhGH trials in IBD.
7. Cystic fibrosis (CF)
7.1 Summary of disease and management
Cystic fibrosis (CF) is an autosomal recessive genetic
condition, primarily affecting the lungs but also the pan-
creas, liver, intestine and other organs. The defect is on the
CF transmembrane conductance regulator (CFTR) gene
(7q31.2) on the long arm of chromosome 7which leads to
absence of normal CFTR protein which is a c-AMP acti-
vated ion channel. As a result of this, decreased chloride
secretion and increased sodium absorption across epithe-
lial surface is seen. In the airways, this causes depletion of
the airway surface liquid and impaired mucociliary clear-
ance which leads to pulmonary infection and inflamma-
tion of the airways. This starts early in life and progresses
to chronic infection and pulmonary inflammation. Pro-
teases, inflammatory cells and cytokines like IL-8, IL-6,
TNF- in CF (360, 361)may lead to ongoing airway wall
inflammation, remodeling and eventually bronchiectasis.
Inflammatory mediators like neutrophil elastase and bac-
terial lipopolysaccharide in turn mediate the inflamma-
tory effects by activating the transcription factor nuclear
factor- which regulates pathways that induce produc-
tion of cytokines. Pathogens such as Pseudomonas aerugi-
nosa, Burkolderia cepacia, Staphylococcus aureus and
Haemophilus influenza eventually colonize the airway se-
cretions of CF individuals.
Recent studies show that TNF gene polymorphism is
associated with disease progression and severity of pul-
monary function (362, 363),while another study foundan
association with gene polymorphism in IL1-, IL-8 and
IL-10 to be associatedwithmore severe lung disease in CF
(364). Cytokines in CF may also impact on the GH-IGF
Figure 10.
Height velocity (HV) and height SDS before and after 6 months of therapy with recombinant hGH (rhGH) or no therapy (Ctrl) in inflammatory
bowel disease.
HV: P  0003 (rhGH – baseline vs6 months), P  058 (Ctrl – baseline vs 6 months) Ht SDS: P  0003 (rhGH – baseline vs 6 months), P  014
(Ctrl – baseline vs 6 months).
Wong SC et al Clin Endocrinol 2011; 74:599–607351
doi: 10.1210/er.2015-1026 press.endocrine.org/journal/edrv 23
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 08 January 2016. at 04:28 For personal use only. No other uses without permission. . All rights reserved.
axis as demonstrated in studies relating inflammatory cy-
tokines to systemic markers of the GH axis. In a group of
young adults with CF, IL-6 was positively associated with
IGFBP-2 (365). Similarly, in a group of prepubertal chil-
dren with CF, change in IL-6 was positively associated
with change in IGFBP-2 (366).
In CF, GI symptoms and signs including failure to pass
meconium in a new born infant is seen. In severe instances
this could be associated with meconium ileus in a small
proportion of infants. Exocrine pancreatic insufficiency
occurs inmost individuals and requires pancreatic enzyme
supplementation. InCFwithpancreatic insufficiency,mu-
cosal inflammation is often seen with raised fecal calpro-
tectin. Fecal calprotectin in CF is also associated with
height SDS (367). Endocrine defects involving damage to
islet cells of the pancreas may lead to CF related diabetes.
CF related diabetes with features of both type 1 and type
2 diabetes mellitus is increasingly recognized especially in
late adolescents. This is often parallels deterioration in
lung function, growth and abnormal bone development.
Current management of CF requires early treatment
and prevention of pulmonary infections with antibiotics,
physiotherapy and nutritional support. Allergic broncho-
pulmonary aspergillosis is an exaggerated immune re-
sponse to Aspergillus fumagitus which is seen in about
4%–11%of individuals with CF, whichwill lead towors-
ening of lung function (368, 369). Oral GC is often used
for prolonged periods as inhaledGC is not effective in this
condition (370).
Structured CF multidisciplinary services and easy ac-
cess to health carers cognizant to the issues in CF have
improved clinical outcome in CF over the last few decades
(371). With increasing survival of people with CF, issues
relating to growthandpubertal developmenthavebecome
a greater concern.
7.2 Growth failure in children with CF
Growth failure and short stature in CF may not have
been given as much attention but with the increasing age
of survivial of these individuals, they may become more
important issues to consider. Severe short stature in CF
may not be a common occurrence. In a recent study of 169
children with CF in the Netherlands, prevalence of short
stature was 8%. However, when target height was taken
into account, this was only 5%. When both delayed mat-
uration and target height were taken into account (height
for bone age adjusted for target height), this was only 1%
(372). Similar to children with JIA and IBD, severe short
stature in contemporary groups of children with CF is
uncommon although poor growth is still seen (372).
Improved clinical care throughmultidisciplinary teams
and the introductionof neonatal screening forCFhasbeen
shown to be associated with improvement in growth.
Studies have shown that ongoing clinical care in specialist
centers all throughout the life cycle leads to improvement
in growth parameters, although it is unclearwhich aspects
of clinical care is associated with improvement in growth.
Interestingly, improvement in growth in thosemanaged in
specialist centers was not associated with in improvement
inpulmonary function (373, 374).Most current published
studies report some association between height and pul-
monary/pancreatic function (375–377) although other
studies show no association of growth with colonization
withPseudomonas aeruginosa (378) and respiratory func-
tion as assessed by FEV1 (379), highlighting the multifac-
torial nature of poor growth in CF.
Addressing nutrition in CF is paramount and may im-
prove linear growth in CF but this needs to be assessed on
an individual basis. Long term supplemental enteral feed-
ing in children with CF using gastrostomy feeding show
improvement in height although height often improves at
least after 18 months of gastrostomy feeding (380–383).
In a contemporary group of children with CF, the preva-
lence of malnutrition was only 7%, whereas 15% were
overweight and 8% were obese (384) and therefore over-
zealous nutritional management should be avoided
Evidence suggest that children with CF identified from
screening exhibit better linear growth compared with
those diagnosed due to clinical symptoms (385). In a study
of 89 CF children identified from neonatal screening, one
third of that cohort had height below the third centile and
half of that cohort had height below the 10th centile (386)
whereas in an older study of children diagnosed from clin-
ical symptoms, 40% had height below the fifth centile at
diagnosis (387).
With the introduction of neonatal screening, it is now
recognized that infants with CF are lighter, shorter and
have smaller head circumference at birth (388–391), as-
sociatedwith reduction in systemic IGF-1 levels fromanal-
ysis of blood spot screening (171). CF genotype itself may
have an impact on growth and this is still poorly docu-
mented in current growth studies in children and adoles-
centswithCD.Childrenhomozygous forF508mutation
had Ht SDS approximately 1 SD below the mean from
infancy to early adolescence (392). Thus, the condition
itself via mechanism still unknown can predispose to
growth failure and this deserves further research.
Poor growth often precede the onset of CF related di-
abetes (23), and can impact on pubertal growth and adult
height (393). Poor growth associated with CF related di-
abetes may not be normalized with insulin treatment even
when started early (393), although currently studies of
insulin treatment in CF diabetes with linear growth out-
comes are limited.CFdiabetes is often diagnosed inmid to
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late adolescents, although with increased awareness and
screening, diagnosis in childhood is not uncommon.
Short stature in CF may have an impact on disease se-
verity as short stature in CF is an independent predictor of
mortality, which may reflect a subgroup with poorer nu-
trition or low grade chronic inflammation and ongoing
pulmonary exacerbations (394). A poorly growing child
with CF and short stature may also have lower lung re-
serve. Thepossible benefit of rhGHtherapyonpulmonary
function in CF will be discussed in a later section.
Similar to children with IBD and JIA, pubertal abnor-
malities are also seen in childrenwithCF.Delay in skeletal
maturation, onset of puberty, attenuated pubertal growth
spurt has been reported in adolescents with CF. Bone age
was reported to be delayed by more than 24 months in
25%of adolescents and compared tohealthy children, age
of peak height velocity as amarker of onset of pubertywas
delayed by 9–10 months in boys and 10–14 months in
girls. GirlswithCF reachmenarche 2 years later than their
healthy peers (395). Older studies show that delayed pu-
berty is present especially in girls with CF despite good
clinical status, with an association of delayed pubertal
onset especially in those with the F508 mutation (396).
However, a recent retrospective study including 729 con-
temporary childrenwithCF, showed that delayed onset of
puberty was not a common occurrence (379)
Adolescents with CF may have lower peak HV com-
pared with healthy adolescents with constitutional delay
in growth and puberty (397). Those individuals with CF
with delayed puberty appear to also have poorer HV dur-
ing pubertal progression (4, 379). One study reporting
body proportions in a group of younger adolescents with
CF showed that their legs were shorter than trunks, al-
though pubertal assessmentwas not reported (5). Delayed
puberty and short stature in CF correlated with less par-
ticipation in social activities, which may be related to the
degree of pulmonary function and disease state. Delayed
puberty in CF was associated with poorer degree of ideal
formation and less positive body attitude (398).
Table 7 summarizes studies with information onAH in
CF (4, 379, 388, 399–403). Interpretation of AH prog-
nosis inCF frompublished studies is difficult given the fact
that it is possible that mortality in some of the more se-
verely affected individuals in adolescence may lead to
more favorable AH of those studies with measurements
conducted in adulthood. On the other hand, survival and
treatment have also improved over the last few decades.
The existing literature of growth in CF suggests that
Table 7. Published Studies Of Adult Height In Childhood Onset Cystic Fibrosis
No patients
Age at
assessment Adult height result
Deviation from mid-
parental height
Hauesler et al. (1994)388 139 19 yr Males 173 cm (25th centile) ND
Females 161.5 cm (25th centile)
Morrison et al. (1997)403 1604 males 20 yr Males Ht SDS 0.7 ND
1452 females Females Ht SDS 0.9
Lai et al. (1999)399 30 Males 19 yr Males Ht SDS 1.2 48% below MPH
Females 17 yr Females Ht SDS 0.1
Aswani et al. (2003)400 US: 27 349
males, 23 797
females




Assael et al. (2009)401 112 “mild
disease”
 20 ys “Mild disease” males 172.4 cm ND
112 “severe
disease”
“Mild disease” female 161.3 cm
“Severe disease” males 171.1 cm
“Severe disease” females 160.1 cm
Boumez et al. (2012)379 398 males 19 yr Males Ht SDS 0.7 ND
331 females Females Ht SDS 0.5
Djik et al. (2011)402 38 clinical
diagnosis




Zhang et al. (2013)4 1862 (269
with parental
height)
21 yr 160 cm (28th centile) MPH 53d centile
CF: cystic fibrosis; Ht: height; cm: centimeter; SDS: standard deviation score; ND: no details; MPH: mid-parental height
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nutritional issues and pulmonary exacerbations are not
sufficient to explain the growth abnormalities in these
children. There is now sufficient evidence to suggest that
poor growth in CF is already seen in the neonatal period
and that CF genotype (F508) plays a contributing role.
Whether this is due to underlying chronic inflammation or
other unknown factors is yet to be determined. In adoles-
cence, furtherworseningof growth andpubertal disorders
may herald the onset of CF related diabetes and this re-
quires early diagnosis and treatment, even though growth
may not fully normalize with insulin therapy. The com-
plex interplay between CF genotype, inflammation, nu-
tritional and endocrine perturbations on growth requires
further investigation.The impact ofCFneonatal screening
on improvement in long term growth outcome needs
clarification.
7.3 Systemic abnormalities in GH/IGF-1 axis in children
with CF
In CF, it is generally accepted that GH resistance also
exists although studies of GH secretion is limited. Using
arginine and clonidine as pharmacological stimulant of
the GH axis in a small group of adolescents with CF, ap-
proximately 50% had peak GH levels  6 mcg/ L and
IGF-1 SDS –0.5, suggesting that relative GH resistance
and GH insufficiency can occur. It was unclear if sex ste-
roid priming was used in this group of children with de-
layed puberty as bone agewas delayed at least by 2.5 years
(404).
Low IGF-1 and IGFBP-3 have been previously reported
in studies in children with CF and show associations with
pulmonary outcomes. In a study of a group of prepubertal
and pubertal children, IGF-1 SDS was –1.2 SD and
IGFBP-3 SD was –0.7 during acute pulmonary exacerba-
tion, althoughanother study reported low IGF-1withnor-
mal IGFBP-3 (365). IGF-1 correlated with forced expira-
tory volume (FEV) 1 (FEV1) and forced vital capacity
(FVC); whereas IGFBP-3 correlated with FVC (405). In a
group of prepubertal children with CF, systemic IGF-1
and bioavailability of IGF-1 correlated with serum
TNF-, providing further evidence to the role of inflam-
mation on the GH-IGF axis in these children. Systemic
IGF-1 showed an association with height in children with
CF although the relationship is modest at best (366, 406–
408). In addition, systemic IGF-1 in CF may also be as-
sociated with weight, protein catabolism (408), lean body
mass (409) and pulmonary function (405, 410).
Other studies report abnormalities in IGF binding pro-
teins with normal systemic IGF-1 in CF in particular sig-
nificantly lower IGFBP-3 and higher IGFBP-1 (406). Re-
duction in bioavailability of IGF-1 due to abnormalities in
IGF binding proteins could account for the growth failure
in CF (366, 411) or alternatively “normal” IGF-1 in the
face of growth failure in CF could also point to IGF-1
resistance. The direct role of IGFP-1 on growth is unclear,
although it shows an association with insulin secretion in
CF, suggesting that IGFBP-1 may have a role in growth
impairment via its effects on glucose homeostasis in CF
(237). Changes in IGF-1 and bioavailability of IGF-1 also
correlated with progressive insulin deficiency (412, 413).
Finally, IGFBP-2 has also been reported to be higher in CF
compared to healthy controls. Change in IGFBP-2 was
associated with changes in IL-6 over a 12 months period
(366).
In summary, systemic evaluation of theGH-IGF axis in
CF have producedmixed results. Low IGF-1may be pres-
ent in infantswithCFwithin the first fewweeksof life. The
interlink of IGFBP-1 with insulin secretion and IGFBP-2
with inflammation may provide further insight into
growth failure inCF, but comprehensive studies of the IGF
axis and the contribution to linear growth are needed.
7.4 Efficacy of rhGH in CF
Clinical trials of the use of rhGH in CF have recently
been evaluated in two systematic reviews including meta-
analysis of published studies (414, 415). Both reviews
have included studies where height or growth rate were
not reported as some of the published studies have been
powered to assess the effects of rhGH on metabolic con-
sequences, body composition and disease parameters.
For this review, we have focused on studies of rhGH in
CF with growth outcomes: Table 8 (416–421) and Table
9 (422–427). To date, there are 6 RCT of rhGH therapy
on linear growth in childrenwithCF.The longest duration
of rhGHclinical trials inCF currently in the literature is 12
months. Change in Ht SDS with rhGH treatment over 12
months in CF range from 0.2 to 0.6. Most published
trials in CF have used rhGH at a dose of 0.3 mg/kg/wk.
OneRCT consisted of two treatment groups; a lower dose
rhGH at 0.273mg/kg/wk and a higher dose rhGH at 0.49
mg/kg/wk in comparison to a untreated group of controls
(425). Both doses of rhGH in that study led to significantly
better growth rateovera short termperiodof6monthsbut
there appears to be a dose dependency of rhGH dose on
linear growth. It is worth noting that current clinical stud-
ies have excluded individuals with CF who have abnor-
malities of glucose homeostasis/ CF related diabetes and
thosewho are colonizedwithBurkholderia cepacia. These
reflect a subgroup of individuals who may be more se-
verely affected who may be more likely to present with
growth failure in the clinical practice to pediatric endo-
crinologists. It is therefore possible that rhGHmay be less
effective in these individuals and care must be taken in
extrapolating results of current clinical trials of rhGH in
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CF when faced with clinical decisions of the role of rhGH
in such individuals.
The three largest RCT of rhGH in CF all show that HV
is approximately 150% higher in the rhGH treated group
compared with control/placebo (422, 424, 425). In the
study by Schnabel et al including two doses of rhGH, the
“lower”doseof rhGHwas comparable to thedoseusedby
Hardin et al (424) and Stavley et al (422). In that study,
height velocity in the group treatedwith the “higher” dose
of rhGH of 0.49 mg/kg/wk was approximately 180%
higher than the control group; whereas height velocity in
the group treated with the “lower” dose of 0.273 mg/
kg/wk was approximately 150% higher than the control
group (425)
The individuals included in the RCT by Schnabel et al
(425) were inmid adolescents as the inclusion criteria was
bone age of 8–18 years, whereas the studies by Hardin et
al (424) and Stalvey et al (422)were younger, pre pubertal
at baseline. Pubertal progression was reported by Stalvey
et al (422) and did not differ between the rhGH and con-
trol group. Hardin et al (424) and Schnabel et al (425)
reported no progression in bone age over the treatment
period.No individual trial has reported response to rhGH
depending on pubertal staging. In the meta-analysis of
pooled data by PhungOJ et al (414), prepubertal children
appeared to have greater increase in HV compared to pu-
bertal children, whereas pubertal children appear to have
better weight gain than prepubertal children with CF
treated with rhGH. In the trial by Hardin et al a suba-
nalysis of change in Ht SDS was similar in those with Ht
SDS  –2.2 and those with Ht SDS  –1.2 (424).
Short term studies of up to 12 months in children and
adolescents with CF, show improvement in Ht SDS of
0.2 to0.6 SD.However, none of the clinical trials have
included older adolescents with CF related diabetes and
therefore the efficacy of rhGH in these adolescents is un-
known. Given the information that suggests that children
with CF are already shorter at birth and in infancy with
low IGF-1 levels, there is a case to consider future clinical
trials of rhGH in younger children. Children with the
F508 genotype should also be targeted for future rhGH
studies given the strong link with growth failure in those
with thegenotype.Comparedwith JIAand IBD,published
trials of rhGH inCFhave included relatively large number
of subjects but durationof follow-up is only 6–12months.
Conducting clinical trials in these individuals can be chal-
lenging given the rest of the burden of clinical care of CF
and QOLmeasures should be evaluated in future studies.
Table 8. Published Non-Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In



















Huseman et al. (1996)420 Prospective 9 1.0 0.30 7.0 5.7 cm/yr 7.8 cm/yr 37% 1.3 0.8 0.5
Hardin et al. (1997)417 Retrospective 24 1.0–2.0 0.29 10.3 3.7 cm/yr 7.8 cm/yr (1st yr) 111% 3.2 - -
6.5 cm/yr (2nd yr) 76%
Alemzadeh et al. (1998)419 Prospective 15 2.0 0.35 3.2 - - - 2.8 0.9 1.9
Hardin et al. (1998)419 Prospective 9 1.0 0.35 5.4–12.2 5.6 cm/yr 8.0 cm/yr 43% 1.9 1.3 0.6
Sackey et al. (1998)421 Prospective 7 1.0 0.16 7.9 0.3 cm/yr 4.1 cm/yr (0.5 yr) 1141% - - -
Hardin et al. (2005)416 Retrospective 13 rhGH 1.0 0.30 13.8 5.1 cm/yr 8.0 cm/yr 57% 1.9 - -
12 historical Ctrl 14.3 5.0 cm/yr 5.0 cm/yr 0% 1.9
yrs; years; rhGH: recombinant human growth hormone; Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS:
standard deviation score




















Hardin D et al. (2001)423 RCT 10 rhGH 1.0 0.30 10.2 3.9 cm/yr 8.0 cm/yr 105% 0.5 0.3 0.2
9 Ctrl 11.4 4.0 cm/yr 4.0 cm/yr 0% 0.6 0.9 0.3
Hutler et al. (2002)426 RCT 6 rhGH 0.5 0.27–0.35 12.1 - 9. cm/yr - 139 cm 141.1 cm -
4 Ctrl 5.4 cm/yr 139 cm 143.3 cm
Hardin et al. (2005)427 RCT 9 rhGH 1.0 0.30 11.6 - 8.0 cm/yr - 1.7 1.1 0.6
9 Ctrl 11.1 3.8 cm/yr 1.7 1.7 0.0
Hardin et al. (2006)424 RCT 32 rhGH 1.0 0.30 10.3 - 8.0 cm/yr - 1.8 - -
29 Ctrl 9.7 5.0 cm/yr 1.9
Schnabel et al. (2007)425 RCT 20 high dose 0.5 0.49 14.3 - 6.8 cm/yr - 2.1 - -
22 low dose 0.27 13.8 5.6 cm/yr 1.8
21 Ctrl (placebo) 14.6 3.8 cm/yr 2.5
Stalvey et al. (2012)422 RCT 36 rhGH 1.0 0.30 9.4 - 8.2 cm/yr - 1.8 1.4 0.4
32 Ctrl 9.4 5.3 cm/yr 1.9 1.9 0.0
yrs; years; rhGH: recombinant human growth hormone; Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS:
standard deviation score
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7.5 Factors affecting growth response to rhGH in CF
7.5.1 Disease and glucocorticoid
Clinical studies of rhGH in CF have not related clinical
outcome, pulmonary function or GC use with responsive-
ness to rhGH therapy.
7.5.2 Systemic IGF-1
In CF, pooled data from subjects previously enrolled in
clinical trials of rhGH revealed that IGF-1 was signifi-
cantly correlated with height and growth rate (408).
7.6 Efficacy of rhGH on disease process in CF
A role of rhGH in improvement of pulmonary disease
in CF has been postulated to be due to increase in absolute
lung volume as a result of increased growth. Another
mechanism could be due to improvement in lean body
mass via the potential anabolic effect of rhGH. In indi-
vidualswithCF, the ability of alveolarmacrophages to kill
Pseudomonas aueroginosa was reduced compared with
healthy controls and this was associated with reduction in
lower IGF-1 levels from broncho-alveolar lavage. Expo-
sure of themacrophages to IGF-1 enhanced their ability to
kill Pseudomonas suggesting that the GH-IGF axis may
havea role in regulationof the immune system inCF (428).
Preliminary evidence also suggest that IGF-1may increase
CF transmembrane conductance regulator which is defec-
tive in individuals with CF, leading to altered airway com-
position and therefore pulmonary infections (429).
In CF, several rhGH studies have shown a reduction in
number of days of hospitalization and the use of IV anti-
biotics (424, 427). These are from studies which did not
include a placebo group.Current rhGH studies inCF have
shown differing results on objective measures of pulmo-
nary function. One study noted significant improvement
in exercise tolerance measured by peak power output and
VO2maxon cycle ergometer in the rhGH treated children
(426). Another rhGH study in a group of children and
young adultswithCF (10–23 years) showed thatmaximal
work load and VO2 max increased significantly with
rhGH therapy over 12months (430). In randomized stud-
ies in CF, FVC and percentage predicted FVC increased
significantly in the rhGH group. FEV1 on the other hand
increased significantly in rhGH treated children but not
percentage predicted FEV1.
It is generally accepted that pulmonary function should
be reported as percentage predicted (normalized to
height). It is possible that improvement in pulmonary
function may not parallel improvement in height in the
short term and that objective improvement in lung func-
tionmay happen later. In addition, a very short child with
poor lung function may have a relatively “normal” per-
centage predicted values as his/her lung function has been
matched to a younger shorter child,making interpretation
of changes in pulmonary status in growth promoting stud-
ies difficult. Future studies should include newer methods
of assessing pulmonary disease in CF which are more sen-
sitive to short term changes in respiratory status and may
not be related to body size.
8. Side effects of rhGH therapy in chronic disease
8.1 Glucose tolerance and insulin sensitivity
rhGH treatment has been reported to be associated
with a decrease in insulin sensitivity in some of the studies
in childrenTurner syndrome (431, 432), PraderWilli Syn-
drome (433, 434), SGA (435) and idiopathic short stature
(436). It may also be associated with an increased risk of
type 2 diabetes mellitus in children with risk factors such
as Turner Syndrome, Prader Willi Syndrome (437). Some
of these conditions themselves have an increased risk of
reduction insulin sensitivity.
Children with inflammatory conditions may also be at
risk of developing insulin resistance as a result of the in-
flammatory process (438) as well as the use of concurrent
GC therapy (439). Approximately 50% of children with
chronic rheumatic conditionsonGChad impairedglucose
tolerance on oral glucose tolerance test (OGTT) (255) In
JIA, rhGH is associated with reduction in insulin sensitiv-
ity, reflected by increased fasting and stimulated insulin
levels (261, 263, 268). In 43 children with JIA who had
previously been treated with rhGH, impaired glucose tol-
erance was observed in 37% and transient diabetes mel-
litus in 5%. There was a higher incidence of impaired
glucose tolerance in those who were treated late possibly
reflecting a longer duration of disease and greater expo-
sure to exogenous glucocorticoid. The two cases that de-
veloped frank diabetes were also overweight (440) .
In children with IBD, therapy with rhGH over a six
months period led to increase in fasting insulin with no
abnormalities of glucose homeostasis. This cohort con-
sisted of most individuals who have not been previously
treatedwithGC.Despite the fact that fasting insulin levels
increased following rhGH therapy in IBD, the clinical sig-
nificance of this is still unclear. The highest level of fasting
insulin was 16 mU/L in a group of individuals in mid and
late adolescence (351). A recent consensus suggests that
the threshold of fasting insulin for diagnosis of insulin
resistance should be a level of  30 mU/L for those in
tanner stage 3 and 4; and 20mU/L for those individuals
in tanner stage 5 (441).
As mentioned previously, current clinical trials in CF
have included individuals with no abnormalities in glu-
cose homeostasis and/or CF related diabetes. The impact
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of rhGH treatment on glucose homeostasis in a child with
CF and established diabetes is unknown. In current clin-
ical trials in CF, rhGH increases fasting glucose but there
were no changes in post prandial or peak glucose with
OGTT. Increased fasting glucose was not seen in shorter
term rhGH studies (6 months). OGTT results were only
available from short term 6 months studies. HbA1C also
did not change with rhGH therapy (414). However, given
the glucose variability in CF related diabetes, future stud-
ies should evaluate glucose homeostasis using continuous
glucose monitoring, which is increasingly recommended
for diagnosis of CF related diabetes (25, 442).
To summarize this section, studies of the use of rhGH
in childrenwith chronic disease treatedwithGC (JIA stud-
ies) show that its use may lead to impaired glucose toler-
ance and type 2 diabetes in approximately 50% and 5%
of treated individuals, respectively. In published rhGH tri-
als in IBD and CF, where use of GC is low, reduction in
insulin sensitivity is seen but no diabetes mellitus have
been reported, although duration of rhGH treatment in
those studies are relatively short. The clinical significance
of raised insulin especially in the prepubertal child during
rhGH treatment on long termmetabolic outcome in these
children is unclear.The extent bywhich rhGHtherapy can
affect glucose homeostasis in individuals with CF and es-
tablished diabetes needs further exploration.
8.2 Skeletal complications
Skeletal complications such as scoliosis (443), Legg-
Calve-Perthes disease (444, 445), slipped capital femoral
epiphysis (446, 447) and osteochondirtis (448) have been
described in children following commencement of rhGH
therapy but systematic surveillance of the spine especially
in rhGH trials in children with chronic inflammatory dis-
ease has not takenplace. In one study, lumbar lordosis and
scoliosis developed in similar numbers of rhGH and con-
trol subjects (5 in each group) with JIA (39). Only one
patient with JIA treated with rhGH developed hip osteo-
chondritis (263); whereas there are no reports of Legg-
Calve-Perthes disease in JIAor IBD. Slippedupper femoral
epiphyses have never been reported in this group of
patients.
There is a concern that the use of higher doses of rhGH
mayadvanceboneageandacceleratepubertal progression
but thishasnotbeenobserved in childrenwith JIAand IBD
(39,351).Ageofonset of puberty in childrenwith JIAwith
follow-up data at final adult height did not differ between
the rhGH and control group (39)
8.3 Disease complications
The current published trials in children with chronic
disease do not raise concerns about rhGH worsening dis-
ease process. Previous studies in GHD and nonGHD chil-
dren following rhGH injections suggest that the immune
system may be activated although it is unclear if the net
effect is an up regulation or down regulation of inflam-
matory cytokines (354–358). Six months therapy with
rhGH was not associated with any significant changes in
a range of proand anti-inflammatory cytokines in children
with IBD (Ref).
Intestinal fibrosis leading to strictures is a complication
ofCD, due to an excessive, irreversible healing response to
chronic inflammation. This is associatedwith overgrowth
of the muscularis mucosa, muscularis propria, excessive
collagen deposition (449) and mesenchymal cell hyper-
plasia (450). In a rat model of colitis, rhGH was reported
to stimulate collagen accumulation in intestinalmyofibro-
blasts (451) but rhGHhas also been reported to reduce the
severity of fibrosis via the induction of suppressor of cy-
tokine signaling proteins (452). There is a need to study
this further especially when rhGH is administered in IBD.
8.4 IGF-1 levels and cancer
The use of replacement rhGH therapy for GH defi-
ciency in children previously treated for childhood cancer
has not been shown to be associated with tumor recur-
renceordevelopmentof new tumors.TheChildhoodCan-
cer Survival Study (CCSS) identified an increased risk of
meningioma in children treated with rhGH (453, 454),
although most of those children had also received radia-
tion to the brain which by itself could be associated with
the development of meningioma (453, 454). In addition,
theCCSS did notmatch rhGH treated patientswith rhGH
naive patients matched for potential confounders for de-
velopment of second tumors. A recent study that matched
for age, site of primary diagnosis, date of radiotherapy,
radiation dose and fractionation found no increased risk
of tumor recurrence or development of second tumors in
rhGH treated patients (455).
An association between increased risks ofmalignancies
has been reported in childrenwith JIA (456–458) and IBD
(459, 460) which may seem to be unrelated to treatment
with immunomodulators and biologic therapy. Currently
there are no reported associations between cancer in chil-
dren with JIA and IBD treated with rhGH. Patients with
acromegaly with excessively high GH and IGF-1 levels
have an increased risk for thyroid, breast and colorectal
carcinoma (461–463). Preliminary evidence also suggests
that patients with IGF-1 deficiency due to genetic muta-
tions in theGHreceptorwith very low/undetectable IGF-1
levels appear to be protected from cancer development
(464).
In JIA and IBD, rhGH leads to an increase in IGF-1 and
IGFBP-3 levels. Bechtold et al’s RCT of rhGH (0.33 mg/
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kg/wk) in JIA showed, reassuringly, that IGF-1 and
IGFBP-3 remained within the normal reference ranges.
Average IGF-1 SDS and average IGFBP-3 SDS during
rhGHwere –0.93 and –0.24, respectively (39). Following
rhGH (0.53 mg/kg/wk) for active CD, IGF-1 SDS in-
creased from –0.4 at baseline to1.8 SD at 12 weeks and
 3.3 SD at 24 weeks. IGF-1 SDS was as high as5SD at
24 weeks which is an issue to be of concern (350) .
Even if systemic IGF-1 levels may not be excessively
raised with relatively “high” dose rhGH in children with
chronic disease, there is the concern that systemic IGF-1
levels may not reflect local expression of IGF-1 (465). An-
imal models of colitis treated with rhGH do not show
increased expression of local IGF-1 (173, 175). Suppres-
sor of cytokine signaling 2 (SOCS2) which may be altered
in chronic inflammation and which negatively regulates
GHaction, has been reported to limit intestinalGHaction
(466, 467). It is possible that this may be a protective
mechanism against high systemic IGF-1 (68, 468). How-
ever, in the mouse model, the protective effect of SOCS2
on the intestines was only seen in older animals. Clearly,
long term surveillance of rhGH treated patients with JIA,
IBD and CF is crucial.
9. IGF-1 and combined GH / IGF-1 in chronic
inflammatory disease
As discussed, GH mediates its effects on target tissues
via direct and indirect effects (41). The direct effects ofGH
are thosemediated via theGHreceptor; indirect effects are
mediated largely via GH related peptides like IGF-1 but
also IGFbindingproteins.While systemic factors (GHand
IGF-1) have independent effects on target organs like the
growth plate, local IGF-1 levels may play a more impor-
tant role in regulation of longitudinal growth.
Given the possibility of a state of functional GH resis-
tance with resultant secondary IGF-1 insufficiency in
chronic inflammation, rhIGF-1 maybe a therapeutic op-
tion for these children (469). The use of rhIGF1 in children
with primary IGF-1 deficiency due tomutations in theGH
receptor is effective in improving linear growth. As op-
posed to complete catch up growth that is seen in children
with GH deficiency treated with rhGH, children with pri-
mary IGF-1 deficiency due to mutations in the GH recep-
tor treated with long term rhIGF-1 still remain signifi-
cantly short (470, 471).
While there are currently no studies of rhIGF-1 in chil-
dren with JIA or IBD, one small randomized trial of
rhIGF-1 (80 mcg/kg twice daily) compared with placebo,
in 7 children with CF failed to show an effect on linear
growth despite normalization of serum IGF-1. The study
showed a reduction in insulin sensitivity with rhIGF-1
treatment. The dose of rhIGF-1 used in the study is within
the recommended starting dose for children with primary
IGF-1 deficiency. Doses up to 120mcg/kg twice daily, can
be used in those children (472). The lack of improvement
of linear growth with conventional dose of rhIGF-1 in the
study with CF may point to a degree of functional IGF-1
resistance. Therefore, higher doses of rhIGF-1 may be
needed to be evaluated in future studies. The potential
adverse effect of hypoglycemia, may preclude the use of
higher dose of rhIGF-1.
Interestingly, systemic IGFBP-3 did not increase with
rhIGF-1 in the study of children with CF. On the other
hand, some but not all studies of rhGH in chronic inflam-
matory conditions have shown that IGFBP-3 can increase
with rhGH treatment. rhIGF-1may in fact reduce the level
of IGFBP-3 and IGF-2 in children with idiopathic short
stature (473). IGFBP-2 did increase with rhIGF-1 treat-
ment in those children. There is also the theoretical pos-
sibility that rhIGF-1 administration may suppress endog-
enousGH secretion. In TNBS ratswith colitis treatedwith
rhIGF-1, there was a rise in IGF1 levels and improved
linear growth linear growth, although growth rate was
only 50% of those of control rats (138).
A trial of rhIGF1 in children with idiopathic short stat-
ure and “low” IGF1 who were approximately 7 years at
baseline, also raised the concern that rhIGF-1 may accel-
erate skeletal maturation, which would be disadvanta-
geous for adult height prognosis.Twelve children (14.1%)
in the two rhIGF-1 arms (80mcg/kg and120mcg/kg twice
daily) as opposed to one (4.4%) in the control arm entered
into puberty during the one year (473). This is in contrast
to the use of higher dose of rhGH in idiopathic short stat-
ure which does not lead to increase in skeletal maturation
and advancement of pubertal progression (474).
A pilot pharmacokinetic study of rh-IGF-1 at 120mcg/
kg/d in eight children with severe CD lead to significant
increase in systemic IGF-1 with almost half the cohort
reaching IGF-1 SDS2.0 (475). The authors developed
a mathematical model that allows prediction of a dose of
rhIGF1 that could be used to maintain systemic IGF-1
below2.5SDof themeanaccounting for age,weight and
PCDAI. Whether this mathematical model is valid over a
longer period of time where changes like growth and pu-
berty may play a greater role is unclear. In addition, given
the fluctuating nature of CD, it is unclear how well the
PCDAI may reflect disease activity in this model. A ran-
domized trial of dose titration of rhGH based on systemic
IGF-1 in children born SGA show less favorable growth
response, although IGF-1 levels remained in the physio-
logical ranges in the dose titrated group (476) .
Given the importance of GH and IGF-1 in longitudinal
growth, combined treatmentwith rhGHand rhIGF-1may
be more physiological and beneficial for growth. Reports
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of combined use in humans show a higher serum concen-
tration of IGF-1 in those who had combined therapy vs
those who had IGF-1 alone, possibly related to the nega-
tive feedback effect of IGF-1 on pituitary GH secretion. A
recent study in female rats, however showed that com-
bined rhGH and rhIGF1 therapy did not lead to further
improvement in linear growth despite an improvement in
cortical bone mass (57). On the other hand, in an exper-
imental ratmodelofuremia, combination therapyappears
to be more effective than rhIGF-1 or rhGH alone as
growthpromoting therapy (477).Theadditionof rhGHto
rhIGF-1 may reverse the insulin suppressive effects of the
latter and may have anticatabolic effects on protein syn-
thesis and muscle mass in seven calorie restricted adults
(478). Given the uncertainties of the efficacy of high dose
rhGH in improving muscle mass in children with chronic
inflammation thus far, combination therapy may confer
advantages in that respect. Combining rhGH with
rhIGF-1 may prevent the glucose lowering effect of IGF-1
(478). Up to 20%of childrenwith idiopathic short stature
treated with rhIGF1 120 mc/kg twice daily were hypogly-
cemic (478). The use of IGF-1 may itself counter the in-
sulin- resistant state thatmay be induced by the use of high
dose rhGH therapy in a group of children who may be
insulin resistant due to their state of chronic inflammation
as well as the use of GC.
Given the evidence of relativeGH resistance in children
with chronic inflammation, there is good biological ratio-
nale to explore the use of rhIGF1 on its own or in com-
bination with rhGH in future well designed collaborative
RCTs.
10. Summary and perspective
10.1 Clinical studies of growth and pubertal disorders
It is clear that clinical outome studies on growth, pu-
bertal development and AH in JIA, IBD and CF treated
with contemporary treatment regimens are needed.
Height, especially AH, needs to be interpreted in the con-
text of the child’s midparental height. As degrees of de-
layed puberty can occur in these children, interpretingHV
needs to be in the context of bone age or pubertal staging.
The use of change in Ht SDS may be a better method of
defining poor growth given the paucity of normative lon-
gitudinal data for HV. Ideally, newer studies should con-
sider reporting growth problems in these children by de-
scribing Ht SDS and change in Ht SDS or HV adjusted for
bone age/puberty (372). Undoubtedly, studies of AH are
needed from contemporary groups of children with
chronic disease, due to the constantly changing landscape
of therapies of chronic disease. Published data onAHmay
never be reflective of current cohort of individuals man-
aged in the clinic, given the time it takes to acquire infor-
mation on long term growth outcome and the possibility
of new therapies.
Outstanding questions in the clinical aspect of growth
and pubertal disorders include
(1)What are the clinical predictors of persistent growth
failure in children with chronic disease? Are there infor-
mative biomarkers eg, disease parameters, inflammatory
cytokines, genetic factors or novel biomarkers early on in
the course of the disease?
(2) What are early predictors for catch-up growth fol-
lowing anticytokine therapy in JIA and IBD? What is the
utility of systemic vs local markers of inflammation for
predictionof growth response?Can composite assessment
of systemic inflammationand systemicmarkersof theGH/
IGF axis increase the prediction?
(3) How much does poor growth and pubertal disor-
ders contribute to abnormal bone accrual and muscle de-
velopment in children with chronic disease?
(4)What is the impactofpoorgrowth, short stature and
delayed puberty on the QOL of adolescents with chronic
disease and do they differ from children with no underly-
ing chronic condition? Are adolescents with chronic dis-
ease more bothered about short stature/poor growth than
delayed puberty?
10.2 Systemic abnormalities of GH/IGF-1 in chronic
disease
This review identified a number of heterogenous stud-
ies of the GH/IGF-1 axis suggesting multiple defect in the
secretion and sensitivity of the GH/IGF-1 axis. Studies
have evaluated IGF-1 and IGFBP-3, although ALS have
not been extensively studied in these conditions.
Important questions to be answered in this area include
(1)Howdoes inflammation impact on formation of the
ternary complex and howdoes this change following ther-
apy of chronic disease especially anticytokine?
(2) What is the link between inflammation and com-
prehensive studies of the ternary complex?
(3) The direct role of IGFbinding proteins on long bone
growth in chronic disease is unclear. We have touched on
the possible role of IGFBP-1 and –2which requires further
clarification. A consideration of the differential effects of
all the binding proteins in chronic disease is needed. For
instance, is there compensatory changes in IGF binding
proteins with chronic inflammation and what is the im-
pact on regulation of growth in chronic disease?
(4) What is the IGF-1 response to rhGH injections as
part of the IGF- generation test and how does this GH
sensitivity change with disease factors?
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10.3 Growth plate regulation in chronic disease
Recent growth plate studies have demonstrated that
proinflammatory cytokines have a direct effect at the level
of the growth plate. GC treatment and malnutrition can
lead to impairment at the level of the growth plate.
Critical research questions to be answered in this area
which may impact on clinical management and research
include
(1)Howdoes cytokine,GCandmalnutrition impact on
local GH and IGF-1 signaling?
(2) How do intrinsic growth plate factors interact with
extrinsic systemic factors in the regulation of growth in
chronic disease?
(3)What is the role of IGF binding proteins at the local
level in chronic disease?
(4) What is the interaction between FGF21 and cyto-
kines andhowmay that impact on local bone growth/local
growth factor signaling?
10.4 Endocrine growth promoting therapies in chronic
disease
There is a need to perform larger,more conclusive stud-
ies of rhGH therapywhich explore the issues raised in this
review. Close collaboration with pediatric rheumatolo-
gists, gastroenterologists and respiratory clinicians would
ensure that appropriate assessment of disease status is per-
formed. Given the complexity of the management of chil-
dren with chronic disease and ongoing burden of the dis-
ease, the opinion of the young person and their families
should be sought in the design of future therapeutic trials
of growth promoting therapies.
Disease activity should be assessed using a range of
methods. For CD, caution is needed if the PCDAI is used.
Data should be presented for the different domains of the
PCDAI, if that is to be used as a disease marker. In CF,
more objective assessment of disease should be evaluated
in future studies other thanhospitalizations. Evaluationof
inflammatory state using inflammatory cytokines should
include assessment of more than 1 cytokine and in addi-
tion measurements of cytokines at local organs (eg, GI
tract, synovial fluid) may bemore accurate butmore chal-
lenging to obtain in research studies.
Research agenda to be considered include
(1) A definitive trial of rhGH on improving growth in
children with chronic disease especially in children with
IBD is needed. This would require collaboration at a na-
tional level at the least.
(2) It is clear that adegreeof functionalGH insensitivity
exists in chronic disease and a higher dose of rhGHmaybe
needed. A study on dose comparison addressing longer
term growth outcome and potential adverse events (ab-
normalities in glucosehomeostasis) in these groupsof chil-
dren are needed. Preliminary evidence from the dose com-
parison trial of rhGH in CF suggest that the percentage
increase in growth rate with the “higher” dose of rhGH
leads to marginal improvement in growth velocity (425) .
(3) It is unclear whether the dose of rhGH should be
titrated by systemic IGF-1 or growth response and this
requires further research.
(4) It is possible that in most children a short course of
therapy for 12 months or during periods of poor growth
may be sufficient for improving growth and prolonged
therapy may not be necessary. Intermittent therapy with
rhGH during periods of relatively poor growth may also
be more cost effective. This method of using rhGH as op-
posed to continued use until final height needs further
exploration.
(5) Future rhGH studies should also examine the effect
of therapy on disease, bone health, body composition,
cardiovascular health and QOL in these children with
chronic disease. It is also unclear if long term outcome of
additionof rhGHto sex steroid confers better height prog-
nosis in those groups of children who are growing slowly
with delayed puberty.
(6) Given that some children with chronic disease con-
tinue to grow slowly with anticytokine therapy (18) and
that improvement in heightwith anticytokinemaybemar-
ginal (21, 219), the role of rhGH in addition to anticyto-
kine therapy should also be explored in future studies
(7) The impact of pubertal induction on growth in
chronic disease deserves higher research priority. There
are numerous unanswered questions on the dose, dura-
tion, route of administration and timingof introductionof
sex steroid in chronic disease.
(8) Given the relative GH resistant state in chronic in-
flammation, the role of combination therapy of rhIGF-1
with rhGHor rhIGF-1 on its ownmay need to be explored
in future well designed trials.
(9) Given the range in deficits in systemic levels of GH/
IGF-1 in chronic disease, can these be used to determine
choice of growth promoting therapies ie, rhGH, rhIGF-1
or combination therapies and therefore growth response?
11. Recommendations for clinical practice
In the absence of extensive data, the off label use of
rhGH in chronic disease in countries where rhGHmay be
available needs to be considered very carefully and dis-
cussed thoroughly with the young person and the family.
rhGH therapy should only be considered after the primary
disease has been treated as aggressively as possible,GCuse
has been minimized and the nutritional status has been
optimized. Inpatientswithdelayedpuberty, this shouldbe
addressed before the consideration of rhGH, although
data on pubertal induction in these children is limited
32 Growth and GH-IGF axis in children with chronic inflammation Endocrine Reviews
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 08 January 2016. at 04:28 For personal use only. No other uses without permission. . All rights reserved.
(479, 480). If rhGH is used, the definition of response in
children with chronic disease is unclear but may be better
defined as change in Ht SDS ( 0.5 SD over twelve
months).
It is ouropinion that fastingglucoseandHbA1Cshould
be considered in all children with chronic disease prior to
commencement of rhGH therapy. Ideally, an OGTT
should be performed at baseline as well. Given the chal-
lenges in interpretation of insulin levels in groups of chil-
dren who are in puberty, there is a case to omit its mea-
surement in the clinical monitoring of children with
chronic disease treated with rhGH therapy. It is our opin-
ion that results from an OGTT may be more useful for
clinical decisionmakingand should thereforebeperfomed
at annual intervals following rhGH therapy as fasting glu-
cose andHbA1C are poor predictors of abnormal glucose
homeostasis in children with chronic disease treated with
rhGH (Simon 2010). In CF, there may be a role of con-
tinuous glucose monitoring for monitoring of glucose ho-
meostasis. In children with evidence of diabetes (eg, CF
diabetes) or impaired glucose tolerance at baseline, there
needs tobe carefuldiscussionwith the family regarding the
risk and benefit of rhGH therapy. In our opinion, the de-
tection of impaired glucose tolerance requires reconsider-
ation of therapy. If oral GC dose can be reduced, we rec-
ommend close monitoring with earlier re-evaluation with
OGTT. If this is not possible, or type 2 diabetes mellitus is
diagnosed on OGTT, reduction of dose of rhGH is rec-
ommended, provided that grwth response is favorable.
Annual assessment of IGF-1 level should be undertaken
but interpretation of IGF-1 levels needs to take into ac-
count of delayed puberty in these children. Regular as-
sessment of puberty and annual bone age is also impor-
tant. Care must be taken in the interpretation of bone age
in children with inflammatory arthritis. Ideally, this
should be performed in the hand not affected by arthritis.
12. Conclusion
The pathophysiology of growth failure in childrenwith
chronic inflammation is multifactorial although the pre-
cise mechanism of the effects of cytokine, glucocorticoid
and malnutrition on systemic and local growth factors is
still unclear. The relative contribution of those factors on
growth failure and the GH/IGF axis is unclear. Clinical
studies in children with JIA, IBD and CF point to multiple
levels of defect of the GH/IGF-1 axis although compre-
hensive evaluationof systemic growth factors in these chil-
dren especially in relation to modern therapy is still lim-
ited. The interaction of the endocrine effects of the GH/
IGF-1 axis with local growth plate regulating factors and
the impact on linear growth in chronic disease is unclear
and needs to be studied.
Although there is some preliminary evidence of the ef-
fects of rhGHon short term linear growth in childrenwith
chronic disease, catch-up growthmaybe incomplete. Lon-
ger term treatment studies and its effects on adult height in
these children should be performed. The impact of im-
provement in linear growth on QOL in these children is
unknown. The cost effectiveness and implication of treat-
ment (burden of injections) needs careful consideration.
Most children with chronic inflammatory disease will
achieve their genetic potentialwith aggressive disease con-
trol and nutritional support. A small subgroup may have
persistent growth failure leading to significant short stat-
ure and these children may benefit from adjuvant growth
promoting therapy.Collaborative clinical trials and trans-
lational studies are needed and to be encouraged.
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